<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int Med Res</journal-id><journal-id journal-id-type="iso-abbrev">J. Int. Med. Res</journal-id><journal-id journal-id-type="publisher-id">IMR</journal-id><journal-id journal-id-type="hwp">spimr</journal-id><journal-title-group><journal-title>The Journal of International Medical Research</journal-title></journal-title-group><issn pub-type="ppub">0300-0605</issn><issn pub-type="epub">1473-2300</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7140199</article-id><article-id pub-id-type="doi">10.1177/0300060519845488</article-id><article-id pub-id-type="publisher-id">10.1177_0300060519845488</article-id><article-categories><subj-group subj-group-type="heading"><subject>Special Issue: Emerging and Reemerging Viral Disease</subject></subj-group></article-categories><title-group><article-title>Virus-induced pathogenesis, vaccine development, and diagnosis of
novel H7N9 avian influenza A virus in humans: a systemic literature
review</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Wen-Hung</given-names></name><xref ref-type="aff" rid="aff1-0300060519845488">1</xref><xref ref-type="aff" rid="aff2-0300060519845488">2</xref></contrib><contrib contrib-type="author"><name><surname>Erazo</surname><given-names>Esmeralda Merari</given-names></name><xref ref-type="aff" rid="aff3-0300060519845488">3</xref></contrib><contrib contrib-type="author"><name><surname>Ishcol</surname><given-names>Max R. Chang</given-names></name><xref ref-type="aff" rid="aff4-0300060519845488">4</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Chih-Yen</given-names></name><xref ref-type="aff" rid="aff2-0300060519845488">2</xref><xref ref-type="aff" rid="aff3-0300060519845488">3</xref></contrib><contrib contrib-type="author"><name><surname>Assavalapsakul</surname><given-names>Wanchai</given-names></name><xref ref-type="aff" rid="aff5-0300060519845488">5</xref></contrib><contrib contrib-type="author"><name><surname>Thitithanyanont</surname><given-names>Arunee</given-names></name><xref ref-type="aff" rid="aff6-0300060519845488">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4183-3872</contrib-id><name><surname>Wang</surname><given-names>Sheng-Fan</given-names></name><xref ref-type="aff" rid="aff2-0300060519845488">2</xref><xref ref-type="aff" rid="aff3-0300060519845488">3</xref><xref ref-type="aff" rid="aff7-0300060519845488">7</xref><xref ref-type="corresp" rid="corresp1-0300060519845488"/></contrib><aff id="aff1-0300060519845488">
<label>1</label>Division of Infectious Disease, Department of Internal Medicine,
Kaohsiung Medical University Hospital, Kaohsiung Medical University,
Kaohsiung</aff><aff id="aff2-0300060519845488">
<label>2</label>Center for Infectious Disease and Cancer Research, Kaohsiung
Medical University, Kaohsiung</aff><aff id="aff3-0300060519845488">
<label>3</label>Department of Medical Laboratory Science and Biotechnology,
Kaohsiung Medical University, Kaohsiung</aff><aff id="aff4-0300060519845488">
<label>4</label>Program in Tropical Medicine, College of Medicine, Kaohsiung
Medical University, Kaohsiung</aff><aff id="aff5-0300060519845488">
<label>5</label>Department of Microbiology, Faculty of Science, Chulalongkorn
University, Bangkok, Thailand</aff><aff id="aff6-0300060519845488">
<label>6</label>Department of Microbiology, Faculty of Science, Mahidol
University, Bangkok, Thailand</aff><aff id="aff7-0300060519845488">
<label>7</label>Department of Medical Research, Kaohsiung Medical University
Hospital, Kaohsiung</aff></contrib-group><author-notes><corresp id="corresp1-0300060519845488">Sheng-Fan Wang, Department of Medical
Laboratory Science and Biotechnology, Kaohsiung Medical University, Kaohsiung
80708. Email: <email>wasf1234@kmu.edu.tw</email></corresp></author-notes><pub-date pub-type="epub"><day>8</day><month>5</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2020</year></pub-date><volume>48</volume><issue>1</issue><elocation-id>0300060519845488</elocation-id><history><date date-type="received"><day>3</day><month>8</month><year>2018</year></date><date date-type="accepted"><day>1</day><month>4</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>Creative Commons Non Commercial CC BY-NC: This article is distributed
under the terms of the Creative Commons Attribution-NonCommercial 4.0
License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract abstract-type="short"><p>H7N9 avian influenza virus (AIV) caused human infections in 2013 in China.
Phylogenetic analyses indicate that H7N9 AIV is a novel reassortant strain with
pandemic potential. We conducted a systemic review regarding virus-induced
pathogenesis, vaccine development, and diagnosis of H7N9 AIV infection in
humans. We followed PRISMA guidelines and searched PubMed, Web of Science, and
Google Scholar to identify relevant articles published between January 2013 and
December 2018. Pathogenesis data indicated that H7N9 AIV belongs to low
pathogenic avian influenza, which is mostly asymptomatic in avian species;
however, H7N9 induces high mortality in humans. Sporadic human infections have
recently been reported, caused by highly pathogenic avian influenza viruses
detected in poultry. H7N9 AIVs resistant to adamantine and oseltamivir cause
severe human infection by rapidly inducing progressive acute community-acquired
pneumonia, multiorgan dysfunction, and cytokine dysregulation; however,
mechanisms via which the virus induces severe syndromes remain unclear. An H7N9
AIV vaccine is lacking; designs under evaluation include synthesized peptide,
baculovirus-insect system, and virus-like particle vaccines. Molecular diagnosis
of H7N9 AIVs is suggested over conventional assays, for biosafety reasons.
Several advanced or modified diagnostic assays are under investigation and
development. We summarized virus-induced pathogenesis, vaccine development, and
current diagnostic assays in H7N9 AIVs.</p></abstract><kwd-group><kwd>H7N9</kwd><kwd>reassortment</kwd><kwd>pathogenesis</kwd><kwd>vaccine</kwd><kwd>review</kwd></kwd-group><funding-group><award-group id="award1-0300060519845488"><funding-source id="funding1-0300060519845488"><institution-wrap><institution>Higher Education Sprout Project - Ministry of Education,
Taiwan </institution></institution-wrap></funding-source><award-id rid="funding1-0300060519845488">TB0357</award-id></award-group><award-group id="award2-0300060519845488"><funding-source id="funding2-0300060519845488"><institution-wrap><institution>Ministry of Science and Technology of the People's Republic
of China</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100002855</institution-id></institution-wrap></funding-source><award-id rid="funding2-0300060519845488">106-2321-B-037-001</award-id></award-group><award-group id="award3-0300060519845488"><funding-source id="funding3-0300060519845488"><institution-wrap><institution>Kaohsiung Medical University Research
Foundation</institution></institution-wrap></funding-source><award-id rid="funding3-0300060519845488">105KMUOR05</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>edited-state</meta-name><meta-value>corrected-proof</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts2</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-0300060519845488"><title>Introduction</title><p>Influenza A is an enveloped virus belonging to the family Orthomyxoviridae that
comprises a negative-sense segmented RNA genome. Influenza viruses are extremely
variable owing to a lack of proofreading during genome replication; therefore,
mutations are continuously accumulated.<sup><xref rid="bibr1-0300060519845488" ref-type="bibr">1</xref><xref rid="bibr2-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr3-0300060519845488" ref-type="bibr">3</xref></sup> Antigenic drift and antigenic
shift are ongoing processes that result in the existence of a large amount of
influenza viruses whose natural reservoirs include wild waterfowl and shorebirds.<sup><xref rid="bibr4-0300060519845488" ref-type="bibr">4</xref></sup> Reports indicate minimal evolution and apparent signs of disease in almost
all natural reservoirs, but the occurrence of accumulated mutations in the genome or
in certain fragments might benefit cross-species transmission.<sup><xref rid="bibr4-0300060519845488" ref-type="bibr">4</xref><xref rid="bibr5-0300060519845488" ref-type="bibr"/><xref rid="bibr6-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr7-0300060519845488" ref-type="bibr">7</xref></sup> Influenza A viruses have the
capacity to evolve rapidly and cause epidemics or even pandemics in domestic
poultry, lower mammals, and humans. Avian influenza virus (AIV) transmission has
been reported in several countries, with sporadic human infections owing to transfer
of the virus from wild birds (e.g., migrating or wild aquatic birds) to domestic
poultry.<sup><xref rid="bibr6-0300060519845488" ref-type="bibr">6</xref>,<xref rid="bibr8-0300060519845488" ref-type="bibr">8</xref></sup>
The first reported AIV infection in humans was caused by H5N1 virus and occurred in
Hong Kong in 1997.<sup><xref rid="bibr6-0300060519845488" ref-type="bibr">6</xref>,<xref rid="bibr9-0300060519845488" ref-type="bibr">9</xref></sup>
Subsequently, AIVs have been continuously monitored and surveyed. Increasingly more
new subtypes of AIVs have emerged in recent decades.<sup><xref rid="bibr6-0300060519845488" ref-type="bibr">6</xref></sup></p><p>In February of 2013, a new atypical influenza virus, H7N9, was first reported in an
87-year-old male in Shanghai, China and the case was confirmed by the Chinese Center
for Disease Control and Prevention on 29 March 2013.<sup><xref rid="bibr10-0300060519845488" ref-type="bibr">10</xref><xref rid="bibr11-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr12-0300060519845488" ref-type="bibr">12</xref></sup> H7N9 is an emerging avian
influenza A virus owing to genetic reassortment.<sup><xref rid="bibr13-0300060519845488" ref-type="bibr">13</xref></sup> This virus was first identified as having low pathogenicity and was
associated with asymptomatic or mild disease in poultry, causing sporadic human
infections.<sup><xref rid="bibr12-0300060519845488" ref-type="bibr">12</xref>,<xref rid="bibr14-0300060519845488" ref-type="bibr">14</xref><xref rid="bibr15-0300060519845488" ref-type="bibr"/><xref rid="bibr16-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr17-0300060519845488" ref-type="bibr">17</xref></sup> A clinical survey of human
infections with H7N9 viruses revealed characteristics of upper and lower respiratory
tract illnesses that varied from mild to moderate (conjunctivitis or uncomplicated
influenza-like illness) and could result in hospitalization.<sup><xref rid="bibr18-0300060519845488" ref-type="bibr">18</xref><xref rid="bibr19-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr20-0300060519845488" ref-type="bibr">20</xref></sup> These novel H7N9 AIVs were
reported to have gradually developed into highly pathogenic avian influenza (HPAI)
viruses,<sup><xref rid="bibr21-0300060519845488" ref-type="bibr">21</xref>,<xref rid="bibr22-0300060519845488" ref-type="bibr">22</xref></sup> indicating multiple increased polybasic amino acids at the
hemagglutinin (HA) cleavage site (PEVPKRKRTAR/GL).<sup><xref rid="bibr22-0300060519845488" ref-type="bibr">22</xref></sup> High mortality rates of about 50% are reported in human cases.<sup><xref rid="bibr18-0300060519845488" ref-type="bibr">18</xref>,<xref rid="bibr22-0300060519845488" ref-type="bibr">22</xref></sup> Phylogenetic
analysis of HA sequences in H7N9 isolates indicates that two major lineages of H7N9
have been established, including the Yangtze River Delta lineage and the Pearl River
Delta lineage.<sup><xref rid="bibr23-0300060519845488" ref-type="bibr">23</xref></sup> Reports indicate that the Yangtze River Delta lineage is broadly dispersed
and was the original source of the H7N9 outbreaks in humans.<sup><xref rid="bibr23-0300060519845488" ref-type="bibr">23</xref>,<xref rid="bibr24-0300060519845488" ref-type="bibr">24</xref></sup> China is
currently facing its sixth epidemic of H7N9 human infection since 2018, and there
has been a total of 1566 laboratory-confirmed human cases reported since 2013.<sup><xref rid="bibr25-0300060519845488" ref-type="bibr">25</xref></sup> The World Health Organization (WHO) reports that three subtypes of AIVs are
currently known to cause human infection, namely, H5, H7, and H9.<sup><xref rid="bibr26-0300060519845488" ref-type="bibr">26</xref></sup> Among them, H5N1 and H7N9 have caused the most human infections.<sup><xref rid="bibr27-0300060519845488" ref-type="bibr">27</xref></sup> This implies a challenge for global public health services in controlling
emerging influenza viruses, even though the number of human infections with the H7N9
influenza virus has gradually decreased with treatment.<sup><xref rid="bibr28-0300060519845488" ref-type="bibr">28</xref></sup> At present, there is no prophylactic vaccine against H7N9 AIV infection
licensed for use in humans. The vaccine candidates currently under investigation
include HA/NA peptide, plasmid-based, baculovirus-insect and mammalian protein
expression system, and virus-like particle (VLP) vaccines.<sup><xref rid="bibr29-0300060519845488" ref-type="bibr">29</xref><xref rid="bibr30-0300060519845488" ref-type="bibr"/><xref rid="bibr31-0300060519845488" ref-type="bibr"/><xref rid="bibr32-0300060519845488" ref-type="bibr"/><xref rid="bibr33-0300060519845488" ref-type="bibr"/><xref rid="bibr34-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr35-0300060519845488" ref-type="bibr">35</xref></sup> Some developed candidate
vaccines are moving on to clinical trials. In addition, accurate and prompt
diagnostic methods that have high sensitivity and specificity are essential for H7N9
influenza disease control and prevention. Several modified, advanced, conventional,
and molecular diagnostic assays have been developed to enhance the capability of
detecting H7N9 antigen or antibody.<sup><xref rid="bibr36-0300060519845488" ref-type="bibr">36</xref><xref rid="bibr37-0300060519845488" ref-type="bibr"/><xref rid="bibr38-0300060519845488" ref-type="bibr"/><xref rid="bibr39-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr40-0300060519845488" ref-type="bibr">40</xref></sup> In this study, we conducted a
systemic literature review of the emergent H7N9 AIVs in China, mainly focusing on
pathogenesis, vaccine development, and diagnosis of human infection.</p></sec><sec sec-type="methods" id="sec2-0300060519845488"><title>Methods</title><sec id="sec3-0300060519845488"><title>Literature retrieval and inclusion criteria</title><p>In this review, we summarized the latest information the pathogenesis of H7N9
influenza virus in humans, vaccine development, and current laboratory assays
for the diagnosis of infection with H7N9 AIV. This review was conducted
according to the PRISMA guidelines, using systematic methods to identify and
select eligible articles from PubMed, Web of Science, and Google Scholar
databases. We used search strings containing a combination of terms including
H7N9 influenza virus, diagnosis, vaccine, and pathogenesis. The systemic search
covered publication dates between January 2013 and December 2018. Search results
were limited to articles published in English language. Articles related to
pharmacodynamics, clinical trials, and meta&#x02010;analyses were excluded. Full&#x02010;text
articles were reviewed to assess their relevance and quality of the methodology.
Articles with the following were excluded: insufficiently detailed materials and
methods; small sample size (n &#x02264; 20); irrelevant or insufficient information
related to the review objectives; articles reporting H7N9 influenza and other
microbes as a combined outcome, use of bioinformatics or mathematical models;
and no quantitative data could be retrieved. We also searched gray literature
such as WHO websites and announcements, and local ministries of health and
centers for disease control and prevention. A flow chart of the systemic
literature search and article selection is shown in <xref ref-type="fig" rid="fig1-0300060519845488">Figure 1</xref>.</p><fig id="fig1-0300060519845488" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Flow chart of criteria and selection guidelines for literature included
in this systemic review</p></caption><graphic xlink:href="10.1177_0300060519845488-fig1"/></fig></sec><sec id="sec4-0300060519845488"><title>Literature analysis</title><p>Two independent reviewers assessed the level of data quality in the selected
articles. Disagreements were resolved by joint discussion and consensus</p></sec><sec id="sec5-0300060519845488"><title>Ethics statement</title><p>In this study, we conducted a literature review regarding the current status of
avian H7N9 influenza virus. Human clinical trials, case reports, and studies
correlated to human ethical issues were excluded from this review. Ethics
approval and informed consent were not required for this study.</p></sec></sec><sec sec-type="results" id="sec6-0300060519845488"><title>Results</title><sec id="sec7-0300060519845488"><title>Pathogenesis of H7N9 influenza infection</title><sec id="sec8-0300060519845488"><title>Emergence of a novel H7N9 virus in China</title><p>H7N9 AIV first appeared in China in 2013 as a new atypical strain arising as
a result of either mutations or genetic reassortment of whole genome
segments, including neuraminidase (NA) genes from wild birds in Korea, HA
genes from duck H7 viruses, and internal genes derived from two distinct
lineages of H9N2 viruses.<sup><xref rid="bibr41-0300060519845488" ref-type="bibr">41</xref>,<xref rid="bibr42-0300060519845488" ref-type="bibr">42</xref></sup> More specifically, the
new H7N9 virus is derived from multiple and sequential reassortment among
HxN9, H7N3, and H9N2 viruses where the H7 and N9 subtypes are from H7N3 and
HxN9 AIVs, respectively, which were subsequently transmitted to and began
circulating in poultry.<sup><xref rid="bibr41-0300060519845488" ref-type="bibr">41</xref>,<xref rid="bibr43-0300060519845488" ref-type="bibr">43</xref></sup> The H7N9 virus is
known to evolve at a rapid rate. Currently, several emerging genotypes of
H7N9 AIVs have been identified, including cocirculating low pathogenic avian
influenza (LPAI) and HPAI, causing infections in poultry and humans.
Previous reports have indicated that in the first wave of the H7N9 influenza
outbreak, a total of 27 genotypes were observed and documented between 2013
and 2014.<sup><xref rid="bibr12-0300060519845488" ref-type="bibr">12</xref>,<xref rid="bibr44-0300060519845488" ref-type="bibr">44</xref></sup> The G0 genotype is predominantly found in human
H7N9 infection whereas the G2, G4, and G5 genotypes are mainly detected in
poultry. Most H7N9 genotypes were detected in the Yangtze River Delta area
in China. More recent genotypic studies have identified dynamic reassortment
of some internal genes among LPAI H7N9/H9N2/H6Ny and HPAI H7N9, as well as
surface genes between the Yangtze River Delta and Pearl River Delta
lineages, resulting in at least 36 genotypes identified in 2017.<sup><xref rid="bibr45-0300060519845488" ref-type="bibr">45</xref>,<xref rid="bibr46-0300060519845488" ref-type="bibr">46</xref></sup> Among
them, three main genotypes predominate, including G1
(A/chicken/Jiangsu/SC537/2013-like strain), G3
(A/chicken/Zhongshan/ZS/2017-like strain), and G11 (A/Anhui/40094/2015-like strain).<sup><xref rid="bibr46-0300060519845488" ref-type="bibr">46</xref></sup></p><p>Most human cases of H7N9 AIV infection have been found in areas endemic for
the virus.<sup><xref rid="bibr18-0300060519845488" ref-type="bibr">18</xref>,<xref rid="bibr19-0300060519845488" ref-type="bibr">19</xref>,<xref rid="bibr42-0300060519845488" ref-type="bibr">42</xref>,<xref rid="bibr47-0300060519845488" ref-type="bibr">47</xref></sup> Closure of live poultry markets effectively
controlled H7N9 epidemics in Shanghai, Nanjing, Hangzhou, and Huzhou during
the first wave of the H7N9 outbreak in China,<sup><xref rid="bibr48-0300060519845488" ref-type="bibr">48</xref></sup> as well as in Shenzhen, Guangzhou, Hangzhou, Foshan, and Ningbo
during the second outbreak wave.<sup><xref rid="bibr47-0300060519845488" ref-type="bibr">47</xref></sup> This suggests that cases of human H7N9 AIV infection resulted from
direct contact with infected poultry. Although animal-to-human transmission
is the main route of infection, some studies have reported the possibility
of human-to-human transmission using clusters of human cases and tracing
data; however, these studies found very low basic reproduction number (R)
estimates.<sup><xref rid="bibr9-0300060519845488" ref-type="bibr">9</xref>,<xref rid="bibr49-0300060519845488" ref-type="bibr">49</xref><xref rid="bibr50-0300060519845488" ref-type="bibr"/><xref rid="bibr51-0300060519845488" ref-type="bibr"/><xref rid="bibr52-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr53-0300060519845488" ref-type="bibr">53</xref></sup> However, Kucharski et&#x000a0;al.<sup><xref rid="bibr43-0300060519845488" ref-type="bibr">43</xref></sup> reported finding no evidence of reduced human-to-human transmission
in the two outbreak waves associated with the closure of live poultry
markets, indicating that higher basic R estimates were reported for the
human-to-human transmission component. Despite the high susceptibility and
occurrence of transmission among household or family members, it has not
been well demonstrated that the H7N9 virus is capable of human-to-human
spread.<sup><xref rid="bibr54-0300060519845488" ref-type="bibr">54</xref>,<xref rid="bibr55-0300060519845488" ref-type="bibr">55</xref></sup> Poultry exposure remains the main risk factor for
human H7N9 infection.<sup><xref rid="bibr43-0300060519845488" ref-type="bibr">43</xref>,<xref rid="bibr55-0300060519845488" ref-type="bibr">55</xref>,<xref rid="bibr56-0300060519845488" ref-type="bibr">56</xref></sup> In addition, travelers
also represent a potential risk factor in the dissemination of H7N9 AIVs
from epidemic regions to non-epidemic areas.<sup><xref rid="bibr3-0300060519845488" ref-type="bibr">3</xref>,<xref rid="bibr57-0300060519845488" ref-type="bibr">57</xref><xref rid="bibr58-0300060519845488" ref-type="bibr"/><xref rid="bibr59-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr60-0300060519845488" ref-type="bibr">60</xref></sup> The WHO has suggested
that the health status of international travelers returning from H7N9
epidemic areas should be assessed on arrival, and these individuals should
be monitored or observed by health care workers for any apparent symptoms
indicative of possible infection .<sup><xref rid="bibr26-0300060519845488" ref-type="bibr">26</xref></sup> Although imported cases of human H7N9 infection have been identified,
the opportunity for spread at community level is unlikely as the virus has
not adapted to humans.<sup><xref rid="bibr3-0300060519845488" ref-type="bibr">3</xref>,<xref rid="bibr57-0300060519845488" ref-type="bibr">57</xref><xref rid="bibr58-0300060519845488" ref-type="bibr"/><xref rid="bibr59-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr60-0300060519845488" ref-type="bibr">60</xref></sup> Furthermore, health
advisories and communications should warn travelers to avoid exposure to
poultry and raw poultry products while visiting affected areas. In people
with a history of travel to affected regions, screening should begin within
2 weeks of departure, prior to the onset of acute respiratory illness.
Patients are encouraged to disclose recent travel histories, and health care
workers should obtain information regarding travel to affected
areas.<sup><xref rid="bibr26-0300060519845488" ref-type="bibr">26</xref>,<xref rid="bibr52-0300060519845488" ref-type="bibr">52</xref>,<xref rid="bibr61-0300060519845488" ref-type="bibr">61</xref></sup> Public health and laboratory partners are suggested
to notify suspected cases during the diagnostic work-up so as to receive
guidance in a timely manner.<sup><xref rid="bibr61-0300060519845488" ref-type="bibr">61</xref></sup></p></sec><sec id="sec9-0300060519845488"><title>Receptors and infection</title><p>The novel H7N9 influenza virus has been reported to be efficiently
transmitted from avian species to humans.<sup><xref rid="bibr62-0300060519845488" ref-type="bibr">62</xref><xref rid="bibr63-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr64-0300060519845488" ref-type="bibr">64</xref></sup> Previous studies
isolated two distinct human H7N9 viruses, A/Shanghai/1/2013 and
A/Anhui/1/2013, carrying Gln-226 and Leu-226 on the HA proteins, respectively,<sup><xref rid="bibr65-0300060519845488" ref-type="bibr">65</xref></sup> which present different receptor-binding properties. The HA molecule
of the A/Anhui/1/2013 strain has dual-receptor specificity, with the ability
to bind to human-type &#x003b1;2,6-linked sialic acid and avian-type &#x003b1;2,3-linked
sialic acid receptors.<sup><xref rid="bibr65-0300060519845488" ref-type="bibr">65</xref>,<xref rid="bibr66-0300060519845488" ref-type="bibr">66</xref></sup> HA receptor binding
affinity and specificity are required for efficient virus transmission
between individuals and between species.<sup><xref rid="bibr67-0300060519845488" ref-type="bibr">67</xref>,<xref rid="bibr68-0300060519845488" ref-type="bibr">68</xref></sup> Reducing the binding
affinities of HA to avian receptors is a critical factor in human-to-human transmission.<sup><xref rid="bibr66-0300060519845488" ref-type="bibr">66</xref></sup></p><p>The receptor-binding tropism of H7N9 changing to human receptors is possibly
owing to the acquisition of two hydrophobic residues by substitution of
Gln226Leu and Gly186Val. These substitutions were found in influenza
pandemic viruses H2N2 and H3N2 in 1957 and 1968, respectively, as well as
aerosol-transmissible H5N1 mutants.<sup><xref rid="bibr68-0300060519845488" ref-type="bibr">68</xref></sup> The receptor binding properties of the human H7N9 virus are diverse,
comprising different lineages of avian H7N9 isolates, but the cleavage
activity of its NA is clearly low for human-type &#x003b1;2,6-linked sialic acid
receptors. Regarding the pathogenicity of H7N9 viruses, disease caused by
virus infection is usually asymptomatic and mortality is rare in chickens,
ducks, and other birds. Similarly, various studies have demonstrated that
H7N9 viruses replicate well in ferrets,<sup><xref rid="bibr69-0300060519845488" ref-type="bibr">69</xref></sup> pigs,<sup><xref rid="bibr70-0300060519845488" ref-type="bibr">70</xref>,<xref rid="bibr71-0300060519845488" ref-type="bibr">71</xref></sup> and mice,<sup><xref rid="bibr71-0300060519845488" ref-type="bibr">71</xref>,<xref rid="bibr72-0300060519845488" ref-type="bibr">72</xref></sup> but are rarely lethal.
Since it first emerged in China in 2013, there have been five reported
outbreak waves of H7N9 AIV, with the majority caused by H7N9 LPAI strains.<sup><xref rid="bibr3-0300060519845488" ref-type="bibr">3</xref></sup> More recently, HPAI H7N9 viruses have been isolated from humans in
Guangdong, with high fatality rates.<sup><xref rid="bibr22-0300060519845488" ref-type="bibr">22</xref>,<xref rid="bibr73-0300060519845488" ref-type="bibr">73</xref></sup> These viruses contain
an insertion of basic amino acids at the HA proteolytic cleavage
site.<sup><xref rid="bibr46-0300060519845488" ref-type="bibr">46</xref>,<xref rid="bibr74-0300060519845488" ref-type="bibr">74</xref></sup> Highly pathogenic H7N9 human isolates were found to
possess HA with a preference for human-type receptors and NA with inhibitor
resistance;<sup><xref rid="bibr22-0300060519845488" ref-type="bibr">22</xref>,<xref rid="bibr75-0300060519845488" ref-type="bibr">75</xref></sup> furthermore, these strains retained a series of
genetic features contributing to human infection, such as 186V in the HA
protein, according to H3 numbering.<sup><xref rid="bibr22-0300060519845488" ref-type="bibr">22</xref>,<xref rid="bibr75-0300060519845488" ref-type="bibr">75</xref></sup> Sequence analysis has
indicated that human HPAI H7N9 clinical isolates, such as
A/Guangdong/17SF006/2017 and A/Taiwan/1/2017 possess mutations in the 627K
domain of the PB2 subunit, conferring efficient replication in mammals.<sup><xref rid="bibr22-0300060519845488" ref-type="bibr">22</xref></sup> In addition, amino acid substitutions associated with drug-resistance
have been detected on NA in these HPAI H7N9 isolates.<sup><xref rid="bibr75-0300060519845488" ref-type="bibr">75</xref></sup></p></sec><sec id="sec10-0300060519845488"><title>Clinical symptoms</title><p>H7N9 AIV has jumped the species barrier, causing sporadic human infections
since 2013. H7N9 human influenza virus A/Anhui/1/2013 has sporadically
infected humans, with a high mortality rate of about 40%. However, earlier
H7N9 isolates lack the multiple basic amino acids at the HA cleavage site
that are usually present on highly pathogenic AIV strains.<sup><xref rid="bibr76-0300060519845488" ref-type="bibr">76</xref>,<xref rid="bibr77-0300060519845488" ref-type="bibr">77</xref></sup>
Clinical observations show that patients with confirmed H7N9 avian influenza
present with high fever (&#x02265;39&#x000b0;C), productive or nonproductive cough, dyspnea,
hypoxia, lower respiratory tract inflammation, shortness of breath, and
infiltrates have also been noted on chest imaging.<sup><xref rid="bibr3-0300060519845488" ref-type="bibr">3</xref>,<xref rid="bibr78-0300060519845488" ref-type="bibr">78</xref></sup> Complications in human
cases of H7N9 AIV infection include respiratory failure, acute respiratory
distress syndrome, septic shock, refractory hypoxemia, rhabdomyolysis,
encephalopathy, acute renal dysfunction, multiple organ dysfunction,
ventilator-associated pneumonia, and bacteremia.<sup><xref rid="bibr3-0300060519845488" ref-type="bibr">3</xref>,<xref rid="bibr78-0300060519845488" ref-type="bibr">78</xref>,<xref rid="bibr79-0300060519845488" ref-type="bibr">79</xref></sup> These features differ
from those of previous human cases of infection with H7 subtype AIV, which
generally presents as mild flu-like illness or conjunctivitis.<sup><xref rid="bibr6-0300060519845488" ref-type="bibr">6</xref></sup> The three first human H7N9 viruses (A/Shanghai/1/2013,
A/Shanghai/2/2013, and A/Anhui/1/2013) isolated from patients were found to
be identical in all eight viral gene segments. However, A/Shanghai/1/2013
has been found to be phylogenetically distinct from the other two strains
mentioned above.<sup><xref rid="bibr80-0300060519845488" ref-type="bibr">80</xref></sup> Compared with human cases of infection with HPAI H7N9 (e.g.,
A/Guangdong/17SF003/2016 or A/Guangdong/17SF006/2017), most patients
infected with A/Shanghai/1/2013 have viral pneumonia and some patients have
displayed acute respiratory distress syndrome (ARDS), especially elderly
people, who also have high fatality rates.<sup><xref rid="bibr22-0300060519845488" ref-type="bibr">22</xref>,<xref rid="bibr81-0300060519845488" ref-type="bibr">81</xref></sup> Overall, the clinical
presentation of HAPI H7N9 infection is similar to that of LPAI H7N9 infection;<sup><xref rid="bibr22-0300060519845488" ref-type="bibr">22</xref></sup> however, fewer patients with HPAI than LPAI H7N9 infection have
underlying conditions.<sup><xref rid="bibr82-0300060519845488" ref-type="bibr">82</xref></sup></p></sec><sec id="sec11-0300060519845488"><title>Host immune response against H7N9 influenza virus</title><p>The pathogenesis of human H7N9 virus that leads to severe outcomes remains
unclear. Previous studies of HPAI H5N1 virus and pandemic (H1N1) 2009 virus
have suggested that poor prognosis in human disease caused by these
influenza viruses might be attributed to a cytokine storm or
hypercytokinemia in the body.<sup><xref rid="bibr83-0300060519845488" ref-type="bibr">83</xref><xref rid="bibr84-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr85-0300060519845488" ref-type="bibr">85</xref></sup> Some studies of H7N9
AIV have analyzed the cytokine and chemokine profiles in human serum samples
from H7N9-infected patients. Reports have showed the presence of high levels
of cytokines and chemokines, such as interleukin (IL)-6, IL-17, IL-2,
monocyte chemotactic protein (MIP)-1, the monokine induced by gamma
interferon (MIG), and macrophage inflammatory protein (MIP)-1&#x003b2;, in the serum
of patients infected with H7N9 AIV.<sup><xref rid="bibr86-0300060519845488" ref-type="bibr">86</xref>,<xref rid="bibr87-0300060519845488" ref-type="bibr">87</xref></sup> Moreover, in patients
with severe H7N9 infection, the expressed levels of IL-6 and IP-10 molecules
are significantly higher than in asymptomatic patients with H7N9 infection.<sup><xref rid="bibr86-0300060519845488" ref-type="bibr">86</xref></sup> However, a previous study using BALB/c and C57BL/6 mouse models
assessed the pathogenicity of H7N9 virus, to examine the association of
proinflammatory cytokines in lung injury and viral clearance. The findings
of that study showed that TNF-&#x003b1; and IFN-&#x003b3; suppress viral gene expression and
increase viral clearance whereas IL-6 and MCP-1 contribute to lung injury in
A/H7N9-infected mice.<sup><xref rid="bibr88-0300060519845488" ref-type="bibr">88</xref></sup> In summary, H7N9 viruses potently induce the expression of
proinflammatory cytokines (IL-2, IL-6, and IL-7) and chemokines (IP-10),
which contributes to the regulation of cellular immune responses.
Alternatively, H7N9 infection also induces strong inflammatory responses,
leading to tissue destruction.</p><p>Clinical observation indicates that patients with severe H7N9 AIV infection
have high serum levels of IP-10 and IL-6, which may reflect the severity of disease.<sup><xref rid="bibr86-0300060519845488" ref-type="bibr">86</xref></sup> In addition, the PB1-F2 protein of the influenza virus has been
implicated in the regulation of polymerase activity, immunopathology,
susceptibility to secondary bacterial infection, and the induction of apoptosis.<sup><xref rid="bibr89-0300060519845488" ref-type="bibr">89</xref></sup> Studies suggest that the PB1-F2 protein may assist in
NLRP3-associated hyperinflammation in human H7N9 influenza virus infections
via the formation of inflammasome in host cells. New treatment strategies
for H7N9 PB1-F2-induced lung inflammation and cellular influx specifically
target NLRP3 inflammasome formation, which may provide effective therapy to
reduce the disease severity level and mortality rate in pathogenic H7N9
infection.</p></sec><sec id="sec12-0300060519845488"><title>Drug resistance</title><p>The newly emerged avian H7N9 influenza virus is known to cause human
infection with high mortality. Antiviral drugs are critical tools for the
control, treatment, and prevention of H7N9 virus infection as humans lack
immunity against H7 subtype influenza viruses. Both M2 ion channel blockers
(adamantanes, amantadine, and rimantadine) and NA inhibitors (oseltamivir,
zanamivir, peramivir, and laninamivir) are used clinically as antiviral
drugs for influenza infection in humans.<sup><xref rid="bibr90-0300060519845488" ref-type="bibr">90</xref><xref rid="bibr91-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr92-0300060519845488" ref-type="bibr">92</xref></sup> Owing to the S31N
mutation in the M2 protein, emerging H7N9 viruses are reported to be
resistant to adamantine antiviral drugs,<sup><xref rid="bibr93-0300060519845488" ref-type="bibr">93</xref></sup> which are therefore not recommended for clinical therapy.
Oseltamivir, generally used as treatment for influenza infection, reduces
the viral load in the respiratory tract of patients. Drug resistance to NA
inhibitors is unusual among influenza viruses. However, some patients with
H7N9 AIV infection have poor clinical outcome. The arginine to lysine
substitution at residue R292K and E119V mutation in NA protein are linked
with resistance to NA inhibitors, including oseltamivir and
peramivir.<sup><xref rid="bibr90-0300060519845488" ref-type="bibr">90</xref>,<xref rid="bibr94-0300060519845488" ref-type="bibr">94</xref><xref rid="bibr95-0300060519845488" ref-type="bibr"/><xref rid="bibr96-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr97-0300060519845488" ref-type="bibr">97</xref></sup>
Ribavirin is a well-characterized, broad-spectrum nucleoside inhibitor,
which is used for the inhibition of viral RNA synthesis and capping of mRNA.
Ribavirin also has antiviral activity against NA inhibitor-resistant H7N9
virus infections.<sup><xref rid="bibr98-0300060519845488" ref-type="bibr">98</xref></sup> Human infections with avian H7N9 influenza virus mainly originate
from contact with infected poultry. An effective strategy to minimize the
risk of human H7N9 infections would be to administer aerosolized ribavirin
to the nasal mucosa. Regarding drug resistance of HPAI H7N9 isolates,
A/Guangdong/17SF003/2016(H7N9) strain has been reported to have NA-292R
residue, similar to A/Anhui/1/2013 (H7N9), and sensitivity to all three NA inhibitors.<sup><xref rid="bibr75-0300060519845488" ref-type="bibr">75</xref></sup> Baloxavir marboxil is a novel inhibitor against influenza virus
cap-dependent endonuclease, which was approved by the US Food and Drug
Administration in October 2018 to treat influenza A and B viruses in Japan
and the United States.<sup><xref rid="bibr99-0300060519845488" ref-type="bibr">99</xref></sup> This new drug might serve as a potential treatment for H7N9 AIV
infections in the near future. We summarize some characteristics and
features of H7N9 virus-induced pathogenesis in <xref rid="table1-0300060519845488" ref-type="table">Table 1</xref>.</p><table-wrap id="table1-0300060519845488" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Summary of the characteristics of H7N9 avian influenza A virus in
humans</p></caption><alternatives><graphic specific-use="table1-0300060519845488" xlink:href="10.1177_0300060519845488-table1"/><table frame="hsides" rules="groups"><thead valign="top"><tr><th rowspan="1" colspan="1">Feature</th><th rowspan="1" colspan="1">Details</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Low pathogenicity avian influenza (LPAI) virusH7N9</td><td rowspan="1" colspan="1">Displays low pathogenicity in poultry with no illness;
highly virulent in humans with severe
symptoms.<sup><xref rid="bibr3-0300060519845488" ref-type="bibr">3</xref>,<xref rid="bibr42-0300060519845488" ref-type="bibr">42</xref>,<xref rid="bibr62-0300060519845488" ref-type="bibr">62</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Highly pathogenic avian influenza (HPAI) virusH7N9</td><td rowspan="1" colspan="1">Displays high pathogenicity in both avian and human
infections.<sup><xref rid="bibr18-0300060519845488" ref-type="bibr">18</xref>,<xref rid="bibr22-0300060519845488" ref-type="bibr">22</xref>,<xref rid="bibr23-0300060519845488" ref-type="bibr">23</xref>,<xref rid="bibr73-0300060519845488" ref-type="bibr">73</xref></sup></td></tr><tr><td rowspan="1" colspan="1">First reported human case (date and location)</td><td rowspan="1" colspan="1">Case reported on February 2013 in Shanghai, China and
confirmed by Chinese CDC on 29 March 2013<sup><xref rid="bibr3-0300060519845488" ref-type="bibr">3</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Age range of confirmed human cases</td><td rowspan="1" colspan="1">Age 2&#x02013;91 years,<sup><xref rid="bibr3-0300060519845488" ref-type="bibr">3</xref>,<xref rid="bibr9-0300060519845488" ref-type="bibr">9</xref></sup> with median age 62 years<sup><xref rid="bibr9-0300060519845488" ref-type="bibr">9</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Ages with higher risk of further complications</td><td rowspan="1" colspan="1">&#x0003c;5 years and &#x0003e;65 years<sup><xref rid="bibr3-0300060519845488" ref-type="bibr">3</xref>,<xref rid="bibr9-0300060519845488" ref-type="bibr">9</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Susceptibility by sex and area</td><td rowspan="1" colspan="1">67% of confirmed cases are males<sup><xref rid="bibr9-0300060519845488" ref-type="bibr">9</xref>,<xref rid="bibr153-0300060519845488" ref-type="bibr">153</xref>,<xref rid="bibr154-0300060519845488" ref-type="bibr">154</xref></sup>Increasing trend in rural areas<sup><xref rid="bibr156-0300060519845488" ref-type="bibr">156</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Transmission exposures</td><td rowspan="1" colspan="1">Being exposed to poultry in places such as live poultry
markets or incidentally via contaminated
surfaces.<sup><xref rid="bibr48-0300060519845488" ref-type="bibr">48</xref>,<xref rid="bibr62-0300060519845488" ref-type="bibr">62</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Transmission source</td><td rowspan="1" colspan="1">Zoonotic: from poultry to humans.<sup><xref rid="bibr9-0300060519845488" ref-type="bibr">9</xref>,<xref rid="bibr49-0300060519845488" ref-type="bibr">49</xref><xref rid="bibr50-0300060519845488" ref-type="bibr"/><xref rid="bibr51-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr52-0300060519845488" ref-type="bibr">52</xref>,<xref rid="bibr56-0300060519845488" ref-type="bibr">56</xref>,<xref rid="bibr120-0300060519845488" ref-type="bibr">120</xref>,<xref rid="bibr140-0300060519845488" ref-type="bibr">140</xref>,<xref rid="bibr149-0300060519845488" ref-type="bibr">149</xref>,<xref rid="bibr150-0300060519845488" ref-type="bibr">150</xref></sup>Human-to-human transmission<sup><xref rid="bibr53-0300060519845488" ref-type="bibr">53</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Host immune response</td><td rowspan="1" colspan="1">Proinflammatory cytokines (IL-2, IL-6 and IL-7) and
chemokines (IP-10) are predominant<sup><xref rid="bibr83-0300060519845488" ref-type="bibr">83</xref><xref rid="bibr84-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr85-0300060519845488" ref-type="bibr">85</xref></sup></td></tr><tr><td rowspan="1" colspan="1">Anti-influenza drug resistance</td><td rowspan="1" colspan="1">Resistance to adamantine,<sup><xref rid="bibr93-0300060519845488" ref-type="bibr">93</xref></sup> oseltamivir,<sup><xref rid="bibr90-0300060519845488" ref-type="bibr">90</xref>,<xref rid="bibr94-0300060519845488" ref-type="bibr">94</xref><xref rid="bibr95-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr96-0300060519845488" ref-type="bibr">96</xref></sup> peramivir,<sup><xref rid="bibr97-0300060519845488" ref-type="bibr">97</xref></sup> and zanamivir<sup><xref rid="bibr97-0300060519845488" ref-type="bibr">97</xref>,<xref rid="bibr161-0300060519845488" ref-type="bibr">161</xref></sup></td></tr></tbody></table></alternatives></table-wrap></sec></sec><sec id="sec13-0300060519845488"><title>Vaccine development</title><p>To reduce the mortality and morbidity rates of influenza virus infection, HA- and
NA-specific neutralizing antibodies can be efficiently generated via
vaccination. Early detection of neutralizing antibodies and rapid availability
of the vaccine are required to prevent H7N9 pandemics. In the development of
H7N9 vaccines, the peptides of HA7 and NA9 molecules of A/Shanghai/2/2013 or
A/Anhui/1/2013 are considered the most promising candidates. These peptide
vaccines are currently undergoing evaluation in clinical trials.</p><p>New technologies for vaccine production, such as cell culture-based antigen
vaccine, live attenuated influenza vaccine (LAIV), DNA vaccine, phylogenetically
related seed strain vaccine, recombinant baculovirus expression vaccine, and
adjuvant-containing H7-based vaccine may be serve to increase vaccination
capabilities.<sup><xref rid="bibr100-0300060519845488" ref-type="bibr">100</xref><xref rid="bibr101-0300060519845488" ref-type="bibr"/><xref rid="bibr102-0300060519845488" ref-type="bibr"/><xref rid="bibr103-0300060519845488" ref-type="bibr"/><xref rid="bibr104-0300060519845488" ref-type="bibr"/><xref rid="bibr105-0300060519845488" ref-type="bibr"/><xref rid="bibr106-0300060519845488" ref-type="bibr"/><xref rid="bibr107-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr108-0300060519845488" ref-type="bibr">108</xref></sup> These technologies would
speed up the production of H7N9 vaccines; however, a long time is likely
required to produce large quantities of available vaccine. Work is ongoing in
developing vaccines based on the HA and NA genes of A/Anhui/1/2013-like H7N9
viruses reassorted with the high-yield master virus A/Puerto Rico/8/34 (PR8) to
enhance H7N9 virus growth capability in eggs, with high total viral and HA
protein yields and attenuated pathogenesis, which has already resulted in
several vaccine candidates.<sup><xref rid="bibr29-0300060519845488" ref-type="bibr">29</xref>,<xref rid="bibr109-0300060519845488" ref-type="bibr">109</xref></sup> LAIVs have been tested
against a pandemic influenza virus.<sup><xref rid="bibr110-0300060519845488" ref-type="bibr">110</xref><xref rid="bibr111-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr112-0300060519845488" ref-type="bibr">112</xref></sup></p><p>Vaccination with a single dose of LAIV is known to be sufficient to stimulate an
immune response against the homologous wild-type strain. Several human clinical
trials are currently evaluating H7-based LAIVs.<sup><xref rid="bibr110-0300060519845488" ref-type="bibr">110</xref>,<xref rid="bibr112-0300060519845488" ref-type="bibr">112</xref><xref rid="bibr113-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr114-0300060519845488" ref-type="bibr">114</xref></sup> Previous outbreaks of
A/mallard/Netherlands/12/2000 (H7N3) and A/Netherlands/219/2003 (H7N7) were
owing to avian-derived H7 strains. These strains have been found to be
phylogenetically related to the HA of H7N9 viruses. Several previous reports
have shown that serum from individuals vaccinated with these vector-based or
inactivated vaccines cross-reacted with H7N9.<sup><xref rid="bibr114-0300060519845488" ref-type="bibr">114</xref><xref rid="bibr115-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr116-0300060519845488" ref-type="bibr">116</xref></sup> Baculovirus-insect cell
expression vectors used in the rapid production of insect cell recombinant
antigens is a practicable strategy in the development of HA-based vaccines.
Other viral vectors (e.g., adenovirus and poxvirus) are also used to prepare vaccines.<sup><xref rid="bibr31-0300060519845488" ref-type="bibr">31</xref></sup> The modified vaccinia virus Ankara and chimpanzee adenoviral ChAdOx1
vaccines are considered safe and immunogenic in humans for inducing long-term
cross-reactive antibody against influenza A virus. These vaccines can be
developed in a short time, to be used against emerging influenza strains.
Moreover, an H7 and N9 molecule-containing vaccine, which is VLP-based from the
A/Anhui/1/13 strain, has been reported to be producible by the baculovirus system.<sup><xref rid="bibr107-0300060519845488" ref-type="bibr">107</xref></sup> A dose of this VLP vaccine administered twice together with an adjuvant
significantly increases the neutralizing ability of HA- and NA-inhibiting
antibody.<sup><xref rid="bibr32-0300060519845488" ref-type="bibr">32</xref>,<xref rid="bibr107-0300060519845488" ref-type="bibr">107</xref></sup> The low-immunogenicity characteristics of H7-based
vaccines have been reported in human<sup><xref rid="bibr117-0300060519845488" ref-type="bibr">117</xref></sup> and animal models.<sup><xref rid="bibr118-0300060519845488" ref-type="bibr">118</xref></sup> Currently, several clinical trials are investigating the effect of
different adjuvants, including MF59 (Novartis), Matrix-M (Novavax), and AS03
(GlaxoSmithKline), to improve generation of protective antibodies.<sup><xref rid="bibr119-0300060519845488" ref-type="bibr">119</xref><xref rid="bibr120-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr121-0300060519845488" ref-type="bibr">121</xref></sup> Regarding poultry
vaccination against H7N9 AIVs, a series of inactivated vaccines has been used
for the control and prevention of H7N9 outbreaks in poultry.<sup><xref rid="bibr100-0300060519845488" ref-type="bibr">100</xref>,<xref rid="bibr122-0300060519845488" ref-type="bibr">122</xref>,<xref rid="bibr123-0300060519845488" ref-type="bibr">123</xref></sup> For
example, an H5/H7 bivalent inactivated influenza vaccine for chickens, ducks,
and geese was introduced in September 2017;<sup><xref rid="bibr124-0300060519845488" ref-type="bibr">124</xref>,<xref rid="bibr125-0300060519845488" ref-type="bibr">125</xref></sup> cases of H7N9 infections
in human and poultry populations decreased after vaccination.<sup><xref rid="bibr126-0300060519845488" ref-type="bibr">126</xref>,<xref rid="bibr127-0300060519845488" ref-type="bibr">127</xref></sup></p></sec><sec id="sec14-0300060519845488"><title>Current diagnosis of H7N9 influenza virus infection</title><p>The first three human cases of infection with influenza H7N9 virus were reported
in February and March 2013 in mainland China.<sup><xref rid="bibr42-0300060519845488" ref-type="bibr">42</xref>,<xref rid="bibr80-0300060519845488" ref-type="bibr">80</xref></sup> Respiratory specimens from
these patients were analyzed using real-time reverse transcription polymerase
chain reaction (RT-PCR), viral culture, and sequencing analysis.<sup><xref rid="bibr128-0300060519845488" ref-type="bibr">128</xref>,<xref rid="bibr129-0300060519845488" ref-type="bibr">129</xref></sup>
Subsequently, cases were mostly confirmed using real time RT-PCR and in certain
cases, viral isolation and serologic testing were also included.<sup><xref rid="bibr42-0300060519845488" ref-type="bibr">42</xref></sup> The proper collection and handling of specimen contributes to the quality
of test results. The most acceptable specimens for diagnosis or identification
of influenza A (H7N9) virus are nasal wash, nasal aspirate, sputum, and
nasopharyngeal swab specimens.<sup><xref rid="bibr36-0300060519845488" ref-type="bibr">36</xref>,<xref rid="bibr130-0300060519845488" ref-type="bibr">130</xref></sup> Throat swabs are not
recommended owing to the low viral load in these specimens; higher viral loads
are found in sputum and tracheal samples.<sup><xref rid="bibr131-0300060519845488" ref-type="bibr">131</xref></sup> The best time for sample collection is near symptom onset, within the
first 3 days as viral shedding decreases after 4&#x02013;5 days. However, shedding lasts
up to 5 days in children.</p><p>Currently, several methods are used in the diagnosis of H7N9 AIV. Routinely,
rapid influenza diagnostic tests (RIDTs) are used along with other confirmatory
tests such as viral isolation, serologic tests, and RT-PCR.<sup><xref rid="bibr130-0300060519845488" ref-type="bibr">130</xref></sup> RIDTs are widely used owing to their ease of use and quick results. RIDTs
are based on antigen detection methods via the use of monoclonal antibodies,
which attach to nucleoproteins on the targeted virus.<sup><xref rid="bibr131-0300060519845488" ref-type="bibr">131</xref></sup> Compared with molecular methods, RIDTs have low sensitivity.<sup><xref rid="bibr132-0300060519845488" ref-type="bibr">132</xref></sup> All RIDTs lack the capability of identifying or differentiating avian
influenza subtypes. Because there are several different AIV subtypes, some more
pathogenic than others, RIDTs that can differentiate between subtypes would
greatly aid in screening, efficient diagnosis, surveillance, and control of
HPAI.<sup><xref rid="bibr133-0300060519845488" ref-type="bibr">133</xref>,<xref rid="bibr134-0300060519845488" ref-type="bibr">134</xref></sup> Such tests would also preclude the need for trained
professionals to carry out testing. Although RIDTs only provide qualitative
measures, the importance of obtaining a positive or negative result enhances
efficient diagnosis, as positive samples can be sent for further analysis.<sup><xref rid="bibr134-0300060519845488" ref-type="bibr">134</xref></sup></p><p>Viral isolation, considered the gold standard for influenza diagnosis, includes
three different techniques: viral isolation using embryonated chicken eggs,
viral culture, and shell viral culture. Viral isolation using embryonated eggs
has some disadvantages, such as it is time consuming, has high biosafety level
(BSL) requirements, and requires the use of eggs.<sup><xref rid="bibr128-0300060519845488" ref-type="bibr">128</xref></sup> These disadvantages are drawbacks for efficient diagnosis; hence, viral
isolation is more useful for subsequent viral analysis and, importantly, in the
initial investigation of an outbreak. Molecular diagnostic tests such as
real-time RT-PCR provide more rapid results for more efficient diagnosis.<sup><xref rid="bibr128-0300060519845488" ref-type="bibr">128</xref></sup> Viral culture uses cell lines, which are infected, incubated, and
monitored. Viral detection in cells can be done using different techniques,
including specific antibody staining, hemadsorption, or immunofluorescence
microscopy. In shell viral culture, cells are grown in 1 dram shell vials and
stained with specific monoclonal antibodies for influenza detection. Serological
tests include hemagglutination inhibition (HAI),<sup><xref rid="bibr135-0300060519845488" ref-type="bibr">135</xref><xref rid="bibr136-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr137-0300060519845488" ref-type="bibr">137</xref></sup> virus neutralization
(VN),<sup><xref rid="bibr136-0300060519845488" ref-type="bibr">136</xref>,<xref rid="bibr138-0300060519845488" ref-type="bibr">138</xref></sup> complement fixation,<sup><xref rid="bibr139-0300060519845488" ref-type="bibr">139</xref>,<xref rid="bibr140-0300060519845488" ref-type="bibr">140</xref></sup> single radial hemolysis
tests (SHR),<sup><xref rid="bibr136-0300060519845488" ref-type="bibr">136</xref>,<xref rid="bibr137-0300060519845488" ref-type="bibr">137</xref>,<xref rid="bibr141-0300060519845488" ref-type="bibr">141</xref></sup> and enzyme-linked immunosorbent assay
(ELISA).<sup><xref rid="bibr128-0300060519845488" ref-type="bibr">128</xref>,<xref rid="bibr136-0300060519845488" ref-type="bibr">136</xref>,<xref rid="bibr142-0300060519845488" ref-type="bibr">142</xref><xref rid="bibr143-0300060519845488" ref-type="bibr"/>&#x02013;<xref rid="bibr144-0300060519845488" ref-type="bibr">144</xref></sup> ELISA,
one of the most commonly performed laboratory assays, uses mono- and polyclonal
antibodies against nucleoproteins on the influenza virus. However, the
sensitivity of ELISA is lower than that of molecular testing.<sup><xref rid="bibr128-0300060519845488" ref-type="bibr">128</xref>,<xref rid="bibr132-0300060519845488" ref-type="bibr">132</xref></sup> HAI is a
common assay based on HA-specific antibody that prevents influenza virus
attachment to red blood cells, but HA has low sensitivity.<sup><xref rid="bibr128-0300060519845488" ref-type="bibr">128</xref>,<xref rid="bibr136-0300060519845488" ref-type="bibr">136</xref>,<xref rid="bibr138-0300060519845488" ref-type="bibr">138</xref>,<xref rid="bibr145-0300060519845488" ref-type="bibr">145</xref></sup> VN
assays require the use of infectious viruses, which are then neutralized with
virus-specific antibodies. VN is more sensitive than HAI, but BSL2 or BSL3
laboratory conditions are required. The SHR assay measures complement-mediated
hemolysis via antigen&#x02013;antibody complex induction; this assay is more sensitive
than HAI.<sup><xref rid="bibr128-0300060519845488" ref-type="bibr">128</xref>,<xref rid="bibr132-0300060519845488" ref-type="bibr">132</xref></sup></p><p>Molecular PCR-based diagnostic tests are commonly performed in the detection and
subtyping of H7N9 AIVs as these are faster than viral isolation and more
sensitive than serologic tests. PCR-based diagnostic tests require RNA
extraction using reagents to inactivate the virus; hence, the BSL requirements
are lower than for viral isolation techniques. The extracted RNA is transcribed
with reverse transcriptase to complementary DNA (cDNA), then amplified using
specific primers for each subtype. With advanced technology, primers are now
able to detect avian influenza A even if the virus is genetically varied.<sup><xref rid="bibr128-0300060519845488" ref-type="bibr">128</xref></sup> A recent advance in PCR-based detection methods for H7N9 AIV is the
multiplex RT-PCR assay, which uses the GenomeLab Gene Expression Profiler (GeXP)
analyzer, a multiplex gene expression analysis platform developed by Beckman
Coulter.<sup><xref rid="bibr146-0300060519845488" ref-type="bibr">146</xref>,<xref rid="bibr147-0300060519845488" ref-type="bibr">147</xref></sup> This assay simultaneously detects four NA serotypes of
the H5 subtype. Both sensitivity and specificity are reportedly high; hence,
this method can be useful in the detection, surveillance, and control of HPAI viruses.<sup><xref rid="bibr148-0300060519845488" ref-type="bibr">148</xref></sup> Detection techniques such as immunochromatographic RIDTs and PCR-based
techniques greatly contribute to rapid, simple, and efficient screening and
confirmation of cases of HPAI H7N9 infection. PCR-based methods further aid in
the surveillance and control of HPAI H7N9 infection as this method has the
advantages of speed, sensitivity, and specificity. We summarize the main tests
performed in the diagnosis or confirmation of H7N9 virus in <xref rid="table2-0300060519845488" ref-type="table">Table 2</xref>.</p><table-wrap id="table2-0300060519845488" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Main tests for diagnosis and/or confirmation of H7N9 avian influenza A
virus (AIV)</p></caption><alternatives><graphic specific-use="table2-0300060519845488" xlink:href="10.1177_0300060519845488-table2"/><table frame="hsides" rules="groups"><thead valign="top"><tr><th rowspan="1" colspan="1">Test</th><th rowspan="1" colspan="1">Sensitivity Specificity</th><th rowspan="1" colspan="1">Advantages</th><th rowspan="1" colspan="1">Disadvantages</th><th rowspan="1" colspan="1">Reference</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Real-time RT-PCR</td><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">
<list list-type="bullet" id="list1-0300060519845488"><list-item><p>Rapid</p></list-item><list-item><p>Lower biosafety level (BSL) requirements</p></list-item><list-item><p>Subtyping</p></list-item><list-item><p>Confirmatory test</p></list-item><list-item><p>Useful in surveillance and control</p></list-item></list>
</td><td rowspan="1" colspan="1">
<list list-type="bullet" id="list2-0300060519845488"><list-item><p>Requires highly trained staff</p></list-item><list-item><p>Not available at all locations</p></list-item></list>
</td><td rowspan="1" colspan="1">[<sup><xref rid="bibr128-0300060519845488" ref-type="bibr">128</xref>,<xref rid="bibr131-0300060519845488" ref-type="bibr">131</xref></sup>]</td></tr><tr><td rowspan="1" colspan="1">Rapid influenza diagnostic test</td><td rowspan="1" colspan="1">Low</td><td rowspan="1" colspan="1">
<list list-type="bullet" id="list3-0300060519845488"><list-item><p>Trained staff not required</p></list-item><list-item><p>Rapid; 15&#x02013;30 minutes</p></list-item><list-item><p>Low cost</p></list-item></list>
</td><td rowspan="1" colspan="1">
<list list-type="bullet" id="list4-0300060519845488"><list-item><p>Does not differentiate between seasonal influenza
and H7N9</p></list-item></list>
</td><td rowspan="1" colspan="1">[<sup><xref rid="bibr131-0300060519845488" ref-type="bibr">131</xref></sup>]</td></tr><tr><td rowspan="1" colspan="1">Viral isolation</td><td rowspan="1" colspan="1">High</td><td rowspan="1" colspan="1">
<list list-type="bullet" id="list5-0300060519845488"><list-item><p>Gold standard</p></list-item><list-item><p>Diagnosis of index cases</p></list-item><list-item><p>For research</p></list-item></list>
</td><td rowspan="1" colspan="1">
<list list-type="bullet" id="list6-0300060519845488"><list-item><p>Requires embryonated eggs or cell culture</p></list-item><list-item><p>Time consuming</p></list-item><list-item><p>High BSL requirements</p></list-item></list>
</td><td rowspan="1" colspan="1">[<sup><xref rid="bibr128-0300060519845488" ref-type="bibr">128</xref>,<xref rid="bibr129-0300060519845488" ref-type="bibr">129</xref></sup>]</td></tr><tr><td rowspan="1" colspan="1">Hemagglutination inhibition assay (HAI)</td><td rowspan="1" colspan="1">Low</td><td rowspan="1" colspan="1">
<list list-type="bullet" id="list7-0300060519845488"><list-item><p>Low cost</p></list-item><list-item><p>Less technical than molecular tests</p></list-item><list-item><p>Rapid</p></list-item><list-item><p>Gold standard for correlation of protection from
influenza vaccine</p></list-item></list>
</td><td rowspan="1" colspan="1">
<list list-type="bullet" id="list8-0300060519845488"><list-item><p>Not multiplex; single antigen identification</p></list-item><list-item><p>Not adequate for evaluation of live attenuated
vaccines</p></list-item><list-item><p>Variability in results from different
laboratories</p></list-item><list-item><p>Requires red blood cells (RBCs), which may affect
results depending on RBC source</p></list-item></list>
</td><td rowspan="1" colspan="1">[<sup><xref rid="bibr128-0300060519845488" ref-type="bibr">128</xref>,<xref rid="bibr136-0300060519845488" ref-type="bibr">136</xref>,<xref rid="bibr138-0300060519845488" ref-type="bibr">138</xref>,<xref rid="bibr145-0300060519845488" ref-type="bibr">145</xref></sup>]</td></tr><tr><td rowspan="1" colspan="1">Virus neutralization assay</td><td rowspan="1" colspan="1">Low</td><td rowspan="1" colspan="1">
<list list-type="bullet" id="list9-0300060519845488"><list-item><p>Capable of detecting low antibody titers</p></list-item><list-item><p>Able to differentiate between pre- and
post-vaccination titers in serum</p></list-item><list-item><p>Differentiates minor titer differences</p></list-item><list-item><p>Higher sensitivity than HAI for detecting
low-titer seroconversion</p></list-item></list>
</td><td rowspan="1" colspan="1">
<list list-type="bullet" id="list10-0300060519845488"><list-item><p>Requires high BSL levels for HPAI</p></list-item><list-item><p>Results vary among laboratories owing to lack of
standardization</p></list-item></list>
</td><td rowspan="1" colspan="1">[<sup><xref rid="bibr136-0300060519845488" ref-type="bibr">136</xref>,<xref rid="bibr138-0300060519845488" ref-type="bibr">138</xref></sup>]</td></tr><tr><td rowspan="1" colspan="1">Single radial hemolysis</td><td rowspan="1" colspan="1">Low</td><td rowspan="1" colspan="1">
<list list-type="bullet" id="list11-0300060519845488"><list-item><p>Small viral or sample quantities required</p></list-item><list-item><p>Ability to analyze multiple number of samples
simultaneously</p></list-item><list-item><p>No pretreatment required</p></list-item><list-item><p>Rapid</p></list-item><list-item><p>Differentiates between different AI virus
strains</p></list-item><list-item><p>Differentiates minor differences in antibody
levels</p></list-item><list-item><p>Inactivated virus detection</p></list-item><list-item><p>Low BSL requirements</p></list-item><list-item><p>Relatively low cost</p></list-item></list>
</td><td rowspan="1" colspan="1">
<list list-type="bullet" id="list12-0300060519845488"><list-item><p>More sensitive for avian influenza B strains</p></list-item></list>
</td><td rowspan="1" colspan="1">[<sup><xref rid="bibr136-0300060519845488" ref-type="bibr">136</xref>,<xref rid="bibr137-0300060519845488" ref-type="bibr">137</xref>,<xref rid="bibr141-0300060519845488" ref-type="bibr">141</xref></sup>]</td></tr><tr><td rowspan="1" colspan="1">Complement fixation</td><td rowspan="1" colspan="1">Intermediate sensitivity, high specificity</td><td rowspan="1" colspan="1">
<list list-type="bullet" id="list13-0300060519845488"><list-item><p>Useful for the detection of antigen&#x02013;antibody
complexes</p></list-item><list-item><p>Easy reading and interpretation of results</p></list-item><list-item><p>Good reproducibility</p></list-item><list-item><p>Useful in analyzing small molecules</p></list-item></list>
</td><td rowspan="1" colspan="1">
<list list-type="bullet" id="list14-0300060519845488"><list-item><p>Requires activation of the complement system</p></list-item><list-item><p>Requires a sampler and indicator system</p></list-item></list>
</td><td rowspan="1" colspan="1">[<sup><xref rid="bibr139-0300060519845488" ref-type="bibr">139</xref>,<xref rid="bibr140-0300060519845488" ref-type="bibr">140</xref></sup>]</td></tr><tr><td rowspan="1" colspan="1">Enzyme-linked immunosorbent assay (ELISA)</td><td rowspan="1" colspan="1">Low</td><td rowspan="1" colspan="1">
<list list-type="bullet" id="list15-0300060519845488"><list-item><p>Low cost</p></list-item><list-item><p>Rapid test</p></list-item><list-item><p>Useful in screening large number of samples</p></list-item><list-item><p>Capable of measuring IgM, IgG, IgA antibodies
(response to AI infection)</p></list-item><list-item><p>Reproducible</p></list-item><list-item><p>Reagents can be standardized</p></list-item><list-item><p>Able to detect broad range of AI virus
antigens</p></list-item></list>
</td><td rowspan="1" colspan="1">
<list list-type="bullet" id="list16-0300060519845488"><list-item><p>Not multiplex, single antigen identification</p></list-item><list-item><p>Cross reactivity may occur</p></list-item></list>
</td><td rowspan="1" colspan="1">[<sup><xref rid="bibr128-0300060519845488" ref-type="bibr">128</xref>,<xref rid="bibr136-0300060519845488" ref-type="bibr">136</xref>,<xref rid="bibr142-0300060519845488" ref-type="bibr">142</xref>,<xref rid="bibr143-0300060519845488" ref-type="bibr">143</xref></sup>]</td></tr></tbody></table></alternatives></table-wrap></sec></sec><sec sec-type="discussion" id="sec15-0300060519845488"><title>Discussion</title><p>Herein, we conducted a systemic literature review for the novel emerged H7N9 AIVs
with respect to pathogenesis, vaccine development, and current diagnosis. Although
current major H7N9 epidemics are in China, this reassorted virus has gradually
evolved from LPAI to HAPI. Currently, HPAI H7N9 AIV has the capability of causing
severe syndromes and inducing high mortality in both avians and humans. The WHO has
also pointed out that among current AIVs, those that cause human infection are H5N1
and H7N9, thereby necessitating the continuous monitoring of genetic and antigenic
change and variation in H7N9 AIVs.<sup><xref rid="bibr26-0300060519845488" ref-type="bibr">26</xref></sup> Understanding the pathogenesis of the virus, developing prophylactic
vaccines, and enhancing the sensitivity and specificity of H7N9 AIV diagnostic
methods are urgently required.</p><p>As an atypical strain with mutations and genetic reassortment, emergence of the novel
H7N9 AIVs in China raises concerns regarding new vaccine development and drug
resistance. The influence of animal infections on human disease propagation places a
large burden on health systems and animal trade controls to prevent the virus
spreading via travelers and animal movement. Although AIVs usually do not infect
people, rare cases of human infection with these viruses have been reported.<sup><xref rid="bibr53-0300060519845488" ref-type="bibr">53</xref></sup> Regarding the transmission route, H7N9 AIVs have been found to cause human
infection, mainly from poultry to humans. Infected birds can shed H7N9 AIVs in
secretions like saliva, mucous, and feces, which can lead to human infection via
mucosal surfaces of the eyes, nose, and mouth or through inhalation of droplets and
dust containing the virus. Unprotected exposure to H7N9 AIVs from infected birds is
currently considered the main risk factor and transmission route. The role of
poultry farms, live animal markets, and retailers might be key in the spread of
disease, as well as inadequate biosafety measures and poor handling of sick or dead
animals. However, some laboratory-confirmed human cases lack evidence of a history
of direct contact with animals, indicating the possibility of human-to-human
transmission.<sup><xref rid="bibr53-0300060519845488" ref-type="bibr">53</xref>,<xref rid="bibr149-0300060519845488" ref-type="bibr">149</xref></sup> To date, several studies have predicted and compared the route
of poultry-to-human or human-to-human transmitted efficiency of H7N9 AIVs using the
reproduction number (R);<sup><xref rid="bibr43-0300060519845488" ref-type="bibr">43</xref>,<xref rid="bibr56-0300060519845488" ref-type="bibr">56</xref>,<xref rid="bibr120-0300060519845488" ref-type="bibr">120</xref>,<xref rid="bibr140-0300060519845488" ref-type="bibr">140</xref>,<xref rid="bibr150-0300060519845488" ref-type="bibr">150</xref></sup> The R is a key indicator of transmission intensity estimated
by fitting the number of poultry-to-human and from human-to-human infections into
mathematical models. The data of these studies showed that the estimated R value for
an H7N9 outbreak was below the epidemic threshold required for sustained
human-to-human transmission, indicating that an H7N9 human-to-human pandemic is
unlikely to occur and most cases of H7N9 AIV infection are owing to poultry-to-human
transmission. Virlogeux et&#x000a0;al.<sup><xref rid="bibr149-0300060519845488" ref-type="bibr">149</xref></sup> recently used an ecological model to evaluate animal-to-human and
human-to-human transmission of H7N9 during the first three epidemic waves in China;
the authors indicated that there was a significant decrease in the incidence of H7N9
cases after live poultry market closures in several major cities of China.
Accordingly, it can be concluded that although H7N9 human-to-human transmission
might be possible, the major transmission route of H7N9 AIVs remains via
poultry-to-human.</p><p>Regarding virus-induced pathogenesis and pathology, H7N9 AIV infection causes mild to
severe syndromes to humans owing to either LPAI or HPAI strains, as compared with
infections in poultry, which are often asymptomatic when infection is with LPAI H7N9
strains. The major element for distinguishing HPAI and LPAI is determination of the
amino acid profiles at the HA cleavage site. Increased basic amino acids have been
proven to enhance the capability of maturation and replication of AIVs. The
mechanism through which LPAI H7N9 viruses induce different pathogenesis in birds and
humans is still not fully understood, suggesting that to determine the virulence of
influenza A virus, it is critical to check the occurrence of variations or mutations
in other viral proteins that are involved in virus replication and dissemination.
Reports have indicated that H7N9 Asian lineage and H5N1 HPAI Asian lineage strains
are mainly responsible for most cases of human illness worldwide to date, and these
also result in the most serious illnesses and highest mortality. Clinical
observation reports indicate that severe symptoms including viral pneumonia,
hypercytokinemia, and even ARDS in cases of death owing to H7N9 AIV infection, which
mainly occur in older people, as compared with H5N1 infection in which severe
symptoms generally occur in younger patients.<sup><xref rid="bibr9-0300060519845488" ref-type="bibr">9</xref>,<xref rid="bibr81-0300060519845488" ref-type="bibr">81</xref>,<xref rid="bibr151-0300060519845488" ref-type="bibr">151</xref>,<xref rid="bibr152-0300060519845488" ref-type="bibr">152</xref></sup></p><p>In addition, comparative cohort studies have indicated that the sex ratio is much
higher in urban than rural areas in infections with both H7N9 and H5N1
viruses.<sup><xref rid="bibr9-0300060519845488" ref-type="bibr">9</xref>,<xref rid="bibr153-0300060519845488" ref-type="bibr">153</xref>,<xref rid="bibr154-0300060519845488" ref-type="bibr">154</xref></sup> The reason might be correlated with sex-based differences in
exposure to AIVs rather than to differences in immunity.<sup><xref rid="bibr9-0300060519845488" ref-type="bibr">9</xref>,<xref rid="bibr153-0300060519845488" ref-type="bibr">153</xref></sup> For instance, higher numbers
of cases of H7N9 infection have been reported among men in Shanghai city, where men
have a greater tendency than women to have more frequent retail exposure to live
poultry. Other possible reasons for this difference have been reported, including
worse prognosis for infected men than infected women, and differences in
health-seeking behaviors.<sup><xref rid="bibr153-0300060519845488" ref-type="bibr">153</xref></sup> However, some reports indicate that differences in immunity between men and
women remain a consideration.<sup><xref rid="bibr155-0300060519845488" ref-type="bibr">155</xref></sup> Recently, Chen et&#x000a0;al.<sup><xref rid="bibr156-0300060519845488" ref-type="bibr">156</xref></sup> reported that an increasing trend of H7N9 human infections in rural areas of
Zhejiang Province in China during 2013&#x02013;2017 was the result of rural live poultry
markets that remained open despite the epidemic; this suggests that closing live
poultry markets is an effective way to control H7N9 human infections.</p><p>In this study, we report that human patients with H7N9 AIV infection develop severe
illness, dysregulation of the cytokine and chemokine response, late viral clearance,
and impaired immunity.<sup><xref rid="bibr157-0300060519845488" ref-type="bibr">157</xref></sup> Induction of pro-inflammatory cytokines by H7N9 is the predominant factor
leading to hypercytokinemia, an important risk factor triggering multiple organ
damage, thereby increasing the mortality rate in human cases of infection with H7N9
AIV.<sup><xref rid="bibr81-0300060519845488" ref-type="bibr">81</xref>,<xref rid="bibr152-0300060519845488" ref-type="bibr">152</xref></sup> Reports have
indicated that peripheral blood mononuclear cells have greater susceptibility to
H7N9 than H5N1 virus, and H7N9 could more efficiently infect B and T lymphocytes
than H5N1 (p&#x0003c;0.01).<sup><xref rid="bibr158-0300060519845488" ref-type="bibr">158</xref></sup> Another study indicated that hypercytokinemia is associated with
interferon-induced transmembrane protein-3 dysfunction, which could be useful in the
prediction of H7N9-induced mortality.<sup><xref rid="bibr159-0300060519845488" ref-type="bibr">159</xref></sup> In addition, H7N9 AIVs show greater tropism for the respiratory epithelium as
well as nasopharynx-associated lymphoid tissues than H5N1 viruses.<sup><xref rid="bibr152-0300060519845488" ref-type="bibr">152</xref></sup> Similar results have been found in H7N9 virus-challenged mice and ferret
models.<sup><xref rid="bibr152-0300060519845488" ref-type="bibr">152</xref>,<xref rid="bibr160-0300060519845488" ref-type="bibr">160</xref></sup> Since the end of 2017, a new H7N9 AIV
(A/Guangdong/17SF006/2017) has been identified as an HPAI strain in China. This HPAI
H7N9 virus was generated from its LPAI counterpart<sup><xref rid="bibr22-0300060519845488" ref-type="bibr">22</xref>,<xref rid="bibr46-0300060519845488" ref-type="bibr">46</xref>,<xref rid="bibr74-0300060519845488" ref-type="bibr">74</xref></sup> and has high affinity for both
human-type &#x003b1;2-6-linked sialic acid and avian-type &#x003b1;2-3-linked sialic acid
receptors.<sup><xref rid="bibr65-0300060519845488" ref-type="bibr">65</xref>,<xref rid="bibr66-0300060519845488" ref-type="bibr">66</xref></sup> These characteristics demonstrate the capability of H7N9
viruses for adaptation and binding, thus opening the door for the virus to develop
drug resistance, thereby presenting a challenge for drug and vaccine development as
the clinical symptoms of these mutants differ from the original H7N9 virus,
including respiratory distress syndrome, septic shock, acute renal dysfunction, and
multiple organ dysfunction.<sup><xref rid="bibr3-0300060519845488" ref-type="bibr">3</xref>,<xref rid="bibr78-0300060519845488" ref-type="bibr">78</xref>,<xref rid="bibr79-0300060519845488" ref-type="bibr">79</xref></sup> These symptoms may be related to the presence of IP-10 and IL-6
in patients with severe H7N9-induced disease, as these induce an acute inflammatory
response and extensive tissue destruction.<sup><xref rid="bibr86-0300060519845488" ref-type="bibr">86</xref></sup></p><p>Regarding drug use and design, targeting NLRP3 inflammosome formation may be
effective in reducing the severity and mortality of H7N9 AIV infection, as humans
lack immunity against H7 subtype influenza viruses. Some patients with H7N9
infection have shown poor outcomes with therapies such as M2 ion channel or NA blockers.<sup><xref rid="bibr94-0300060519845488" ref-type="bibr">94</xref></sup> In addition, some reports have indicated that H7N9 viruses acquire drug
resistance against NA inhibitors via substitutions, which is correlated with amino
acid substitutions; R292K confers the highest increase in oseltamivir half-maximal
inhibitory concentration (IC<sub>50</sub>), E119D confers the highest
IC<sub>50</sub> of zanamivir, and H274Y confers highly reduced inhibition by oseltamivir.<sup><xref rid="bibr161-0300060519845488" ref-type="bibr">161</xref></sup> The need for new anti-influenza viral drugs is urgent. Testing some
alternatives in H7N9 treatment is advisable, such as intranasal administration of
ribavirin and baloxavir marboxil, as these have demonstrated effectiveness with
other influenza viruses.<sup><xref rid="bibr98-0300060519845488" ref-type="bibr">98</xref>,<xref rid="bibr99-0300060519845488" ref-type="bibr">99</xref></sup></p><p>In prevention and prophylaxis of H7N9 AIVs, it is necessary to develop vaccines that
can easily induce neutralizing antibody and generate CD8<sup>+</sup> cytotoxic T
cells for virus neutralization and clearance, respectively. LAIV, H7 and N9
molecule-containing vaccine, and recombinant VLP vaccines based on A/Anhui/1/13
strain have shown effective stimulation of the specific immune response and no
cross-reaction with other virus strains.<sup><xref rid="bibr100-0300060519845488" ref-type="bibr">100</xref>,<xref rid="bibr162-0300060519845488" ref-type="bibr">162</xref></sup> Clinical trials and animal
studies have revealed that much remains to be accomplished in the development of new
vaccines, and their efficacy relies on targeting different phylogenetically related
genotypic strains of H7N9 AIV.<sup><xref rid="bibr108-0300060519845488" ref-type="bibr">108</xref></sup> Human contact with infected poultry and global travel is unlikely to
diminish, and the pathogenesis of H7N9 AIVs will likely persist. Therefore,
strategies should be focused on understanding more about the impact of new therapies
and prophylaxis to control circulating viruses.</p><p>Diagnostic tools or platforms with high sensitivity and specificity for detection of
viral antigens or antibodies of H7N9 AIVs have been widely developed. Although viral
culture is conventionally viewed as the gold standard in virological assays,
real-time RT-PCR is currently suggested as an alternative gold standard as the
former method requires specific BSL laboratory conditions and experienced staff.
However, RIDTs are quick and easy to perform, so these tests have become essential
at sites where real-time RT-PCR is unavailable. Current RIDTs have the capability of
detecting strains of both influenza A and B. However, they have low sensitivity with
new strains and are unable to differentiate between subtypes; therefore, the rate of
false negatives is higher.<sup><xref rid="bibr131-0300060519845488" ref-type="bibr">131</xref></sup>RIDTs provide rapid detection of the presence or absence of viral analytes in
patient samples; a major advantage of RIDTs is that results can be obtained within
15&#x02013;30 minutes.<sup><xref rid="bibr131-0300060519845488" ref-type="bibr">131</xref></sup> As mentioned, there are several different subtypes of H7N9 AIVs circulating
in China, some more pathogenic than others. With the advantage of speedy results,
RIDTs that can differentiate between subtypes would provide a breakthrough for rapid
screening and diagnosis, especially of HPAI H7N9 and AIVs such as H5N1.<sup><xref rid="bibr134-0300060519845488" ref-type="bibr">134</xref></sup> RIDTs can be performed at points-of-care for first-line influenza virus screening.<sup><xref rid="bibr134-0300060519845488" ref-type="bibr">134</xref></sup> This would help in patient diagnosis as well as the detection of asymptomatic
cases or mild symptom cases, thus preventing further spread.<sup><xref rid="bibr163-0300060519845488" ref-type="bibr">163</xref></sup> In addition, several advanced or modified assays and platforms for detecting
H7N9 AIVs are under investigation, such as modified surface plasmon resonance,<sup><xref rid="bibr39-0300060519845488" ref-type="bibr">39</xref></sup> enzyme-induced metallization,<sup><xref rid="bibr164-0300060519845488" ref-type="bibr">164</xref></sup> reverse transcription-loop-mediated isothermal amplification assay,<sup><xref rid="bibr165-0300060519845488" ref-type="bibr">165</xref></sup> and chip-based biosensors.<sup><xref rid="bibr166-0300060519845488" ref-type="bibr">166</xref></sup></p><p>This study has some limitations. We selected articles written in English only; in
addition, we excluded small cohort studies and clinical trials and focused mainly on
study results in human cases of AIV infection. These selection criteria might have
resulted in the loss of certain important information and experimental results
published in Chinese or other non-English languages, as well as some important
observations from small cohorts and animal studies.</p></sec><sec sec-type="conclusions" id="sec16-0300060519845488"><title>Conclusion</title><p>Currently, H7N9 influenza virus is disseminated among aquatic birds and poultry,
increasing their adaption and virulence in humans. Although this virus primarily
exists in mainland China, increasingly more imported cases have been reported in
other countries. Clinical H7N9 AIV isolates have been proven to have resistant to
adamantine and oseltamivir, which are commonly used in influenza therapy. This
highlights that new antiviral drugs, continuous genotype identification, and new
vaccines against H7N9 influenza viruses are urgently needed. In addition, the
development of accurate and rapid testing methods is necessary for the surveillance
and control of H7N9 virus infections.</p></sec></body><back><ack><title>Acknowledgements</title><p>The authors wish to thank the staff from Kaohsiung Medical University Hospital and
Taiwan CDC for their assistance in providing essential and meaningful information of
current H7N9 influenza virus.</p></ack><sec id="sec17-0300060519845488"><title>Author&#x02019;s contribution</title><p>WHW prepared the manuscript. EME, MRCI, and CYL helped to prepare the draft. EME and
MRCI assisted in language editing. WA and AT revised the draft. SFW conceived the
study and revised the draft.</p></sec><sec id="sec18-0300060519845488"><title>Declaration of conflicting interest</title><p>The authors declare that there is no conflict of interest.</p></sec><sec id="sec19-0300060519845488"><title>Funding</title><p>This work was supported by grants from the Center for Infectious Disease and Cancer
Research, Kaohsiung Medical University (KMUTP105E00 and KMUTP 105E04), a grant from
Higher Education Sprout Project - Ministry of Education, Taiwan (TB0357), and grants
from the Ministry of Science and Technology, R.O.C. (108-2918-I-037-001).</p></sec><ref-list content-type="numbered"><title>References</title><ref id="bibr1-0300060519845488"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>RB</given-names></name><name><surname>Chen</surname><given-names>HL.</given-names></name></person-group>
<article-title>An overview of the recent outbreaks of the avian-origin influenza
A (H7N9) virus in the human.</article-title>
<source>J Chin Med Assoc</source>
<year>2013</year>; <volume>76</volume>: <fpage>245</fpage>&#x02013;<lpage>248</lpage>.
2013/05/09. DOI: 10.1016/j.jcma.2013.04.003.<pub-id pub-id-type="pmid">23651506</pub-id></mixed-citation></ref><ref id="bibr2-0300060519845488"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>YM</given-names></name><name><surname>Klenk</surname><given-names>HD.</given-names></name></person-group>
<article-title>Erratum: H7N9 avian influenza virus - search and
re-search.</article-title>
<source>Emerg Microbes Infect</source>
<year>2013</year>; <volume>2</volume>: <fpage>e26</fpage>. 2013/05/01. DOI:
10.1038/emi.2013.26.<pub-id pub-id-type="pmid">26039114</pub-id></mixed-citation></ref><ref id="bibr3-0300060519845488"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Human infection with a novel
avian-origin influenza A (H7N9) virus.</article-title>
<source>N Engl J Med</source>
<year>2013</year>; <volume>368</volume>:
<fpage>1888</fpage>&#x02013;<lpage>1897</lpage>. 2013/04/13. DOI:
10.1056/NEJMoa1304459.<pub-id pub-id-type="pmid">23577628</pub-id></mixed-citation></ref><ref id="bibr4-0300060519845488"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prosser</surname><given-names>DJ</given-names></name><name><surname>Hungerford</surname><given-names>LL</given-names></name><name><surname>Erwin</surname><given-names>RM</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Mapping avian influenza
transmission risk at the interface of domestic poultry and wild
birds</article-title>. <source>Front Public Health</source>
<year>2013</year>; <volume>1</volume>: <fpage>28</fpage>. 2013/12/19. DOI:
10.3389/fpubh.2013.00028.<pub-id pub-id-type="pmid">24350197</pub-id></mixed-citation></ref><ref id="bibr5-0300060519845488"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uyeki</surname><given-names>TM</given-names></name><name><surname>Cox</surname><given-names>NJ.</given-names></name></person-group>
<article-title>Global concerns regarding novel influenza A (H7N9) virus
infections.</article-title>
<source>N Engl J Med</source>
<year>2013</year>; <volume>368</volume>:
<fpage>1862</fpage>&#x02013;<lpage>1864</lpage>. 2013/04/13. DOI:
10.1056/NEJMp1304661.<pub-id pub-id-type="pmid">23577629</pub-id></mixed-citation></ref><ref id="bibr6-0300060519845488"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poovorawan</surname><given-names>Y</given-names></name><name><surname>Pyungporn</surname><given-names>S</given-names></name><name><surname>Prachayangprecha</surname><given-names>S</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Global alert to avian
influenza virus infection: from H5N1 to H7N9.</article-title>
<source>Pathog Glob Health</source>
<year>2013</year>; <volume>107</volume>: <fpage>217</fpage>&#x02013;<lpage>223</lpage>.
2013/08/07. DOI: 10.1179/2047773213y.0000000103.<pub-id pub-id-type="pmid">23916331</pub-id></mixed-citation></ref><ref id="bibr7-0300060519845488"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>SH</given-names></name><name><surname>Gilbert</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>MC</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Historical prevalence and
distribution of avian influenza virus A(H7N9) among wild
birds.</article-title>
<source>Emerg Infect Dis</source>
<year>2013</year>; <volume>19</volume>: <fpage>2031</fpage>&#x02013;<lpage>2033</lpage>.
2013/11/28. DOI: 10.3201/eid1912.130649.<pub-id pub-id-type="pmid">24274638</pub-id></mixed-citation></ref><ref id="bibr8-0300060519845488"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>CY</given-names></name><name><surname>Ai</surname><given-names>JH.</given-names></name></person-group>
<article-title>[Virological characteristics of avian influenza A H7N9
virus].</article-title>
<source>Zhongguo Dang Dai Er Ke Za Zhi</source>
<year>2013</year>; <volume>15</volume>: <fpage>405</fpage>&#x02013;<lpage>408</lpage>.
2013/06/26.<pub-id pub-id-type="pmid">23791049</pub-id></mixed-citation></ref><ref id="bibr9-0300060519845488"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowling</surname><given-names>BJ</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Lau</surname><given-names>EH</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Comparative epidemiology of
human infections with avian influenza A H7N9 and H5N1 viruses in China: a
population-based study of laboratory-confirmed cases.</article-title>
<source>Lancet</source>
<year>2013</year>; <volume>382</volume>: <fpage>129</fpage>&#x02013;<lpage>137</lpage>.
2013/06/28. DOI: 10.1016/S0140-6736(13)61171-X.<pub-id pub-id-type="pmid">23803488</pub-id></mixed-citation></ref><ref id="bibr10-0300060519845488"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>RA.</given-names></name></person-group>
<article-title>H7N9 influenza: something old, something new.</article-title>
<source>Int J Clin Pract</source>
<year>2013</year>; <volume>67</volume>: <fpage>935</fpage>&#x02013;<lpage>938</lpage>.
2013/08/06. DOI: 10.1111/ijcp.12214.<pub-id pub-id-type="pmid">23910504</pub-id></mixed-citation></ref><ref id="bibr11-0300060519845488"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Avian influenza A(H7N9)
virus infections, Shanghai, China.</article-title>
<source>Emerg Infect Dis</source>
<year>2013</year>; <volume>19</volume>: <fpage>1179</fpage>&#x02013;<lpage>1181</lpage>.
2013/06/19. DOI: 10.3201/eid1907.130523.<pub-id pub-id-type="pmid">23769147</pub-id></mixed-citation></ref><ref id="bibr12-0300060519845488"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>TT</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Dissemination, divergence
and establishment of H7N9 influenza viruses in China.</article-title>
<source>Nature</source>
<year>2015</year>; <volume>522</volume>: <fpage>102</fpage>&#x02013;<lpage>105</lpage>.
DOI: 10.1038/nature14348.<pub-id pub-id-type="pmid">25762140</pub-id></mixed-citation></ref><ref id="bibr13-0300060519845488"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Su</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Sequential reassortments
underlie diverse influenza H7N9 genotypes in China.</article-title>
<source>Cell Host Microbe</source>
<year>2013</year>; <volume>14</volume>: <fpage>446</fpage>&#x02013;<lpage>452</lpage>.
DOI: 10.1016/j.chom.2013.09.001.<pub-id pub-id-type="pmid">24055604</pub-id></mixed-citation></ref><ref id="bibr14-0300060519845488"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Mild illness in avian
influenza A(H7N9) virus-infected poultry worker, Huzhou, China, April
2013</article-title>. <source>Emerg Infect Dis</source>
<year>2013</year>; <volume>19</volume>: <fpage>1885</fpage>&#x02013;<lpage>1888</lpage>.
2013/11/12. DOI: 10.3201/eid1911.130717.<pub-id pub-id-type="pmid">24209963</pub-id></mixed-citation></ref><ref id="bibr15-0300060519845488"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreijtz</surname><given-names>JH</given-names></name><name><surname>Kroeze</surname><given-names>EJ</given-names></name><name><surname>Stittelaar</surname><given-names>KJ</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Low pathogenic avian
influenza A(H7N9) virus causes high mortality in ferrets upon intratracheal
challenge: a model to study intervention strategies</article-title>.
<source>Vaccine</source>
<year>2013</year>; <volume>31</volume>: <fpage>4995</fpage>&#x02013;<lpage>4999</lpage>.
2013/07/03. DOI: 10.1016/j.vaccine.2013.06.071.<pub-id pub-id-type="pmid">23816392</pub-id></mixed-citation></ref><ref id="bibr16-0300060519845488"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Deaths associated with avian
influenza A(H7N9) virus in China.</article-title>
<source>Ann Intern Med</source>
<year>2013</year>; <volume>159</volume>: <fpage>159</fpage>&#x02013;<lpage>160</lpage>.
2013/07/17. DOI: 10.7326/0003-4819-159-2-201307160-00022,
10.7326/0003-4819-159-2-201307160-00669.<pub-id pub-id-type="pmid">23856693</pub-id></mixed-citation></ref><ref id="bibr17-0300060519845488"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Association between adverse
clinical outcome in human disease caused by novel influenza A H7N9 virus and
sustained viral shedding and emergence of antiviral
resistance.</article-title>
<source>Lancet</source>
<year>2013</year>; <volume>381</volume>:
<fpage>2273</fpage>&#x02013;<lpage>2279</lpage>. 2013/06/04. DOI:
10.1016/S0140-6736(13)61125-3.<pub-id pub-id-type="pmid">23726392</pub-id></mixed-citation></ref><ref id="bibr18-0300060519845488"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>M</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Preliminary epidemiology of
human infections with highly pathogenic avian influenza A(H7N9) virus,
China, 2017.</article-title>
<source>Emerg Infect Dis</source>
<year>2017</year>; <volume>23</volume>: <fpage>1355</fpage>&#x02013;<lpage>1359</lpage>.
2017/06/06. DOI: 10.3201/eid2308.170640.<pub-id pub-id-type="pmid">28580900</pub-id></mixed-citation></ref><ref id="bibr19-0300060519845488"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XY</given-names></name><name><surname>Chai</surname><given-names>CL</given-names></name><name><surname>Li</surname><given-names>FD</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Epidemiology of human
infections with avian influenza A(H7N9) virus in the two waves before and
after October 2013 in Zhejiang province, China.</article-title>
<source>Epidemiol Infect</source>
<year>2015</year>; <volume>143</volume>:
<fpage>1839</fpage>&#x02013;<lpage>1845</lpage>. 2014/10/08. DOI:
10.1017/S095026881400257X.<pub-id pub-id-type="pmid">25286879</pub-id></mixed-citation></ref><ref id="bibr20-0300060519845488"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Xue</surname><given-names>M</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Spatial characteristics and
the epidemiology of human infections with avian influenza A(H7N9) virus in
five waves from 2013 to 2017 in Zhejiang Province, China.</article-title>
<source>PLoS One</source>
<year>2017</year>; <volume>12</volume>: <fpage>e0180763</fpage>. 2017/07/28.
DOI: 10.1371/journal.pone.0180763.<pub-id pub-id-type="pmid">28750032</pub-id></mixed-citation></ref><ref id="bibr21-0300060519845488"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaisocherova</surname><given-names>H</given-names></name><name><surname>Brynda</surname><given-names>E</given-names></name><name><surname>Homola</surname><given-names>J.</given-names></name></person-group>
<article-title>Functionalizable low-fouling coatings for label-free biosensing
in complex biological media: advances and applications.</article-title>
<source>Anal Bioanal Chem</source>
<year>2015</year>; <volume>407</volume>:
<fpage>3927</fpage>&#x02013;<lpage>3953</lpage>. DOI:
10.1007/s00216-015-8606-5.<pub-id pub-id-type="pmid">25821150</pub-id></mixed-citation></ref><ref id="bibr22-0300060519845488"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>C</given-names></name><name><surname>Mok</surname><given-names>CKP</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Human infection with highly
pathogenic avian influenza A(H7N9) virus, China.</article-title>
<source>Emerg Infect Dis</source>
<year>2017</year>; <volume>23</volume>: <fpage>1332</fpage>&#x02013;<lpage>1340</lpage>.
2017/06/06. DOI: 10.3201/eid2308.170600.<pub-id pub-id-type="pmid">28580899</pub-id></mixed-citation></ref><ref id="bibr23-0300060519845488"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Two outbreak sources of
influenza A (H7N9) viruses have been established in China.</article-title>
<source>J Virol</source>
<year>2016</year>; <volume>90</volume>: <fpage>5561</fpage>&#x02013;<lpage>5573</lpage>.
DOI: 10.1128/JVI.03173-15.<pub-id pub-id-type="pmid">27030268</pub-id></mixed-citation></ref><ref id="bibr24-0300060519845488"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Sudden emergence of human
infections with H7N9 avian influenza A virus in Hubei province, central
China.</article-title>
<source>Sci Rep</source>
<year>2018</year>; <volume>8</volume>: <fpage>2486</fpage>. 2018/02/08. DOI:
10.1038/s41598-018-20988-9.<pub-id pub-id-type="pmid">29410505</pub-id></mixed-citation></ref><ref id="bibr25-0300060519845488"><label>25</label><mixed-citation publication-type="other"><collab>Centers for Disease
Control</collab> and Prevention. <collab>Asian Lineage Avian
Influenza</collab>
<article-title>A(H7N9) virus</article-title>. <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/flu/avianflu/h7n9-virus.htm">https://www.cdc.gov/flu/avianflu/h7n9-virus.htm</ext-link>.</mixed-citation></ref><ref id="bibr26-0300060519845488"><label>26</label><mixed-citation publication-type="other"><collab>World Health Organization.</collab>
Emergencies preparedness, response. Human infection with avian influenza A(H7N9)
virus &#x02013; update. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/don/2014_03_07/en/">https://www.who.int/csr/don/2014_03_07/en/</ext-link>.</mixed-citation></ref><ref id="bibr27-0300060519845488"><label>27</label><mixed-citation publication-type="other"><collab>World Health Organization. Fact
sheets. Influenza (Avian</collab> and other zoonotic). <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic">https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic</ext-link>).</mixed-citation></ref><ref id="bibr28-0300060519845488"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatta</surname><given-names>M</given-names></name><name><surname>Zhong</surname><given-names>G</given-names></name><name><surname>Chiba</surname><given-names>S</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Effectiveness of whole,
inactivated, low pathogenicity influenza A(H7N9) vaccine against
antigenically distinct, highly pathogenic H7N9 virus.</article-title>
<source>Emerg Infect Dis</source>
<year>2018</year>; <volume>24</volume>: <fpage>1910</fpage>&#x02013;<lpage>1913</lpage>.
2018/09/19. DOI: 10.3201/eid2410.180403.<pub-id pub-id-type="pmid">30226171</pub-id></mixed-citation></ref><ref id="bibr29-0300060519845488"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Shirakura</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Development of a high-yield
reassortant influenza vaccine virus derived from the A/Anhui/1/2013 (H7N9)
strain.</article-title>
<source>Vaccine</source>
<year>2016</year>; <volume>34</volume>: <fpage>328</fpage>&#x02013;<lpage>333</lpage>.
2015/12/15. DOI: 10.1016/j.vaccine.2015.11.050.<pub-id pub-id-type="pmid">26657023</pub-id></mixed-citation></ref><ref id="bibr30-0300060519845488"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jonge</surname><given-names>J</given-names></name><name><surname>Isakova-Sivak</surname><given-names>I</given-names></name><name><surname>van Dijken</surname><given-names>H</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>H7N9 live attenuated
influenza vaccine is highly immunogenic, prevents virus replication, and
protects against severe bronchopneumonia in ferrets.</article-title>
<source>Mol Ther</source>
<year>2016</year>; <volume>24</volume>: <fpage>991</fpage>&#x02013;<lpage>1002</lpage>.
2016/01/23. DOI: 10.1038/mt.2016.23.<pub-id pub-id-type="pmid">26796670</pub-id></mixed-citation></ref><ref id="bibr31-0300060519845488"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Liepkalns</surname><given-names>JS</given-names></name><name><surname>Hassan</surname><given-names>AO</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>A highly immunogenic vaccine
against A/H7N9 influenza virus.</article-title>
<source>Vaccine</source>
<year>2016</year>; <volume>34</volume>: <fpage>744</fpage>&#x02013;<lpage>749</lpage>.
2016/01/15. DOI: 10.1016/j.vaccine.2015.12.062.<pub-id pub-id-type="pmid">26765287</pub-id></mixed-citation></ref><ref id="bibr32-0300060519845488"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Characterization of humoral
responses induced by an H7N9 influenza virus-like particle vaccine in BALB/C
mice.</article-title>
<source>Viruses</source>
<year>2015</year>; <volume>7</volume>: <fpage>4369</fpage>&#x02013;<lpage>4384</lpage>.
2015/08/08. DOI: 10.3390/v7082821.<pub-id pub-id-type="pmid">26248076</pub-id></mixed-citation></ref><ref id="bibr33-0300060519845488"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pillet</surname><given-names>S</given-names></name><name><surname>Racine</surname><given-names>T</given-names></name><name><surname>Nfon</surname><given-names>C</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Plant-derived H7 VLP vaccine
elicits protective immune response against H7N9 influenza virus in mice and
ferrets.</article-title>
<source>Vaccine</source>
<year>2015</year>; <volume>33</volume>: <fpage>6282</fpage>&#x02013;<lpage>6289</lpage>.
2015/10/04. DOI: 10.1016/j.vaccine.2015.09.065.<pub-id pub-id-type="pmid">26432915</pub-id></mixed-citation></ref><ref id="bibr34-0300060519845488"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Pushko</surname><given-names>P</given-names></name><name><surname>Tretyakova</surname><given-names>I</given-names></name></person-group>
<article-title>. Recombinant hemagglutinin and virus-like particle vaccines for
H7N9 influenza virus</article-title>. <source>J Vaccines Vaccin</source>
<year>2015</year>; <volume>6</volume>: pii: <fpage>287</fpage>. 2015/11/03. DOI:
10.4172/2157-7560.1000287.<pub-id pub-id-type="pmid">26523241</pub-id></mixed-citation></ref><ref id="bibr35-0300060519845488"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biggerstaff</surname><given-names>M</given-names></name><name><surname>Reed</surname><given-names>C</given-names></name><name><surname>Swerdlow</surname><given-names>DL</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Estimating the potential
effects of a vaccine program against an emerging influenza pandemic&#x02013;United
States.</article-title>
<source>Clin Infect Dis</source>
<year>2015</year>; <volume>60</volume>: <fpage>S20</fpage>&#x02013;<lpage>S29</lpage>.
2015/04/17. DOI: 10.1093/cid/ciu1175.<pub-id pub-id-type="pmid">25878298</pub-id></mixed-citation></ref><ref id="bibr36-0300060519845488"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name></person-group>
<article-title>2014 update of the Chinese guidelines for diagnosis and treatment
of avian influenza A(H7N9) virus infection.</article-title>
<source>Chin Med J (Engl)</source>
<year>2014</year>; <volume>127</volume>:
<fpage>2543</fpage>&#x02013;<lpage>2547</lpage>. 2014/07/06.<pub-id pub-id-type="pmid">24985598</pub-id></mixed-citation></ref><ref id="bibr37-0300060519845488"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakauchi</surname><given-names>M</given-names></name><name><surname>Takayama</surname><given-names>I</given-names></name><name><surname>Takahashi</surname><given-names>H</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Development of a reverse
transcription loop-mediated isothermal amplification assay for the rapid
diagnosis of avian influenza A (H7N9) virus infection.</article-title>
<source>J Virol Methods</source>
<year>2014</year>; <volume>204</volume>: <fpage>101</fpage>&#x02013;<lpage>104</lpage>.
2014/04/22. DOI: 10.1016/j.jviromet.2014.03.028.<pub-id pub-id-type="pmid">24747008</pub-id></mixed-citation></ref><ref id="bibr38-0300060519845488"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Laboratory diagnosis of
avian influenza virus H7N9 infection in a renal transplant
recipient</article-title>. <source>Int J Clin Exp Med</source>
<year>2014</year>; <volume>7</volume>: <fpage>451</fpage>&#x02013;<lpage>455</lpage>.
2014/03/07.<pub-id pub-id-type="pmid">24600505</pub-id></mixed-citation></ref><ref id="bibr39-0300060519845488"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>YF</given-names></name><name><surname>Wang</surname><given-names>WH</given-names></name><name><surname>Hong</surname><given-names>YW</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Simple strategy for rapid
and sensitive detection of avian influenza A H7N9 virus based on
intensity-modulated SPR biosensor and new generated
antibody.</article-title>
<source>Anal Chem</source>
<year>2018</year>; <volume>90</volume>: <fpage>1861</fpage>&#x02013;<lpage>1869</lpage>.
2018/01/13. DOI: 10.1021/acs.analchem.7b03934.<pub-id pub-id-type="pmid">29327590</pub-id></mixed-citation></ref><ref id="bibr40-0300060519845488"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Tao</surname><given-names>Q</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Serologic assay for
avian-origin influenza A (H7N9) virus in adults of Shanghai, Guangzhou and
Yunnan, China.</article-title>
<source>J Clin Virol</source>
<year>2014</year>; <volume>60</volume>: <fpage>305</fpage>&#x02013;<lpage>308</lpage>.
2014/05/06. DOI: 10.1016/j.jcv.2014.04.006.<pub-id pub-id-type="pmid">24793969</pub-id></mixed-citation></ref><ref id="bibr41-0300060519845488"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name></person-group>, <etal>et&#x000a0;al.</etal>
<article-title>Genetic tuning of the novel avian influenza A(H7N9) virus during
interspecies transmission, China, 2013</article-title>. <source>Euro
Surveill</source>
<year>2014</year>; <volume>19</volume>: pii: <fpage>20836</fpage>.
2014/07/06.<pub-id pub-id-type="pmid">24993557</pub-id></mixed-citation></ref><ref id="bibr42-0300060519845488"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Epidemiology of human
infections with avian influenza A(H7N9) virus in China.</article-title>
<source>N Engl J Med</source>
<year>2014</year>; <volume>370</volume>: <fpage>520</fpage>&#x02013;<lpage>532</lpage>.
2013/04/26. DOI: 10.1056/NEJMoa1304617.<pub-id pub-id-type="pmid">23614499</pub-id></mixed-citation></ref><ref id="bibr43-0300060519845488"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kucharski</surname><given-names>AJ</given-names></name><name><surname>Mills</surname><given-names>HL</given-names></name><name><surname>Donnelly</surname><given-names>CA</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Transmission potential of
influenza A(H7N9) virus, China, 2013-2014.</article-title>
<source>Emerg Infect Dis</source>
<year>2015</year>; <volume>21</volume>: <fpage>852</fpage>&#x02013;<lpage>855</lpage>.
2015/04/22. DOI: 10.3201/eid2105.141137.<pub-id pub-id-type="pmid">25897624</pub-id></mixed-citation></ref><ref id="bibr44-0300060519845488"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Dynamic reassortments and
genetic heterogeneity of the human-infecting influenza A (H7N9)
virus.</article-title>
<source>Nat Commun</source>
<year>2014</year>; <volume>5</volume>: <fpage>3142</fpage>. 2014/01/25. DOI:
10.1038/ncomms4142.<pub-id pub-id-type="pmid">24457975</pub-id></mixed-citation></ref><ref id="bibr45-0300060519845488"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>An</surname><given-names>X</given-names></name><name><surname>Jiao</surname><given-names>Y</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Co-circulation of multiple
genotypes of influenza A (H7N9) viruses in eastern China,
2016-2017.</article-title>
<source>Arch Virol</source>
<year>2018</year>; <volume>163</volume>:
<fpage>1779</fpage>&#x02013;<lpage>1793</lpage>. DOI:
10.1007/s00705-018-3800-3.<pub-id pub-id-type="pmid">29541846</pub-id></mixed-citation></ref><ref id="bibr46-0300060519845488"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Quan</surname><given-names>L</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Evolutionary genotypes of
influenza A (H7N9) viruses over five epidemic waves in
China.</article-title>
<source>Infect Genet Evol</source>
<year>2017</year>; <volume>55</volume>: <fpage>269</fpage>&#x02013;<lpage>276</lpage>.
DOI: 10.1016/j.meegid.2017.09.027.<pub-id pub-id-type="pmid">28943407</pub-id></mixed-citation></ref><ref id="bibr47-0300060519845488"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>JT</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Poultry market closures and
human infection with influenza A(H7N9) virus, China,
2013-14.</article-title>
<source>Emerg Infect Dis</source>
<year>2014</year>; <volume>20</volume>: <fpage>1891</fpage>&#x02013;<lpage>1894</lpage>.
2014/10/24. DOI: 10.3201/eid2011.140556.<pub-id pub-id-type="pmid">25340354</pub-id></mixed-citation></ref><ref id="bibr48-0300060519845488"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>JT</given-names></name><name><surname>Cowling</surname><given-names>BJ</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Effect of closure of live
poultry markets on poultry-to-person transmission of avian influenza A H7N9
virus: an ecological study.</article-title>
<source>Lancet</source>
<year>2014</year>; <volume>383</volume>: <fpage>541</fpage>&#x02013;<lpage>548</lpage>.
2013/11/05. DOI: 10.1016/S0140-6736(13)61904-2.<pub-id pub-id-type="pmid">24183056</pub-id></mixed-citation></ref><ref id="bibr49-0300060519845488"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Horby</surname><given-names>PW</given-names></name><name><surname>Tsang</surname><given-names>TK</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Differences in the
epidemiology of human cases of avian influenza A(H7N9) and A(H5N1) viruses
infection.</article-title>
<source>Clin Infect Dis</source>
<year>2015</year>; <volume>61</volume>: <fpage>563</fpage>&#x02013;<lpage>571</lpage>.
2015/05/06. DOI: 10.1093/cid/civ345.<pub-id pub-id-type="pmid">25940354</pub-id></mixed-citation></ref><ref id="bibr50-0300060519845488"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>L</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Household transmissibility
of avian influenza A (H7N9) virus, China, February to May 2013 and October
2013 to March 2014.</article-title>
<source>Euro Surveill</source>
<year>2015</year>; <volume>20</volume>: <fpage>21056</fpage>.
2015/03/20.<pub-id pub-id-type="pmid">25788253</pub-id></mixed-citation></ref><ref id="bibr51-0300060519845488"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudge</surname><given-names>JW</given-names></name><name><surname>Coker</surname><given-names>R.</given-names></name></person-group>
<article-title>Human to human transmission of H7N9.</article-title>
<source>BMJ</source>
<year>2013</year>; <volume>347</volume>: <fpage>f4730</fpage>. 2013/08/08. DOI:
10.1136/bmj.f4730.<pub-id pub-id-type="pmid">23920349</pub-id></mixed-citation></ref><ref id="bibr52-0300060519845488"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>Qian</surname><given-names>YH</given-names></name><name><surname>Bao</surname><given-names>CJ</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Probable person to person
transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013:
epidemiological investigation.</article-title>
<source>BMJ</source>
<year>2013</year>; <volume>347</volume>: <page-range>f4752</page-range>.
2013/08/08. DOI: 10.1136/bmj.f4752.</mixed-citation></ref><ref id="bibr53-0300060519845488"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>E</given-names></name><name><surname>Bao</surname><given-names>C</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Clusters of human infection
and human-to-human transmission of avian influenza A(H7N9) virus,
2013-2017</article-title>. <source>Emerg Infect Dis</source>
<year>2018</year>; <volume>24</volume>: <fpage>397</fpage>&#x02013;<lpage>400</lpage>.
2017/11/23. DOI: 10.3201/eid2402.171565.</mixed-citation></ref><ref id="bibr54-0300060519845488"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Spatio-temporal pattern
analysis for evaluation of the spread of human infections with avian
influenza A(H7N9) virus in China, 2013-2014.</article-title>
<source>BMC Infect Dis</source>
<year>2017</year>; <volume>17</volume>: <fpage>704</fpage>. 2017/10/27. DOI:
10.1186/s12879-017-2781-2.<pub-id pub-id-type="pmid">29065855</pub-id></mixed-citation></ref><ref id="bibr55-0300060519845488"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Limited human-to-human
transmission of avian influenza A(H7N9) virus, Shanghai, China, March to
April 2013</article-title>. <source>Euro Surveill</source>
<year>2014</year>; <volume>19</volume>: pii: <fpage>20838</fpage>.
2014/07/06.<pub-id pub-id-type="pmid">24993556</pub-id></mixed-citation></ref><ref id="bibr56-0300060519845488"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Tang</surname><given-names>S</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Transmission potential of
the novel avian influenza A(H7N9) infection in mainland
China.</article-title>
<source>J Theor Biol</source>
<year>2014</year>; <volume>352</volume>: <fpage>1</fpage>&#x02013;<lpage>5</lpage>.
2014/03/13. DOI: 10.1016/j.jtbi.2014.02.038.<pub-id pub-id-type="pmid">24607746</pub-id></mixed-citation></ref><ref id="bibr57-0300060519845488"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name></person-group>
<article-title>Human infection with avian influenza A(H7N9) virus in Shanghai:
current status and future trends</article-title>. <source>Chin Med J
(Engl)</source>
<year>2014</year>; <volume>127</volume>:
<fpage>1973</fpage>&#x02013;<lpage>1976</lpage>. 2014/05/16.<pub-id pub-id-type="pmid">24824266</pub-id></mixed-citation></ref><ref id="bibr58-0300060519845488"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jian</surname><given-names>SW</given-names></name><name><surname>Liu</surname><given-names>DP</given-names></name><name><surname>Chang</surname><given-names>FY.</given-names></name></person-group>
<article-title>Risk assessment of human infection with avian influenza A (H7N9)
virus in Taiwan.</article-title>
<source>J Formos Med Assoc</source>
<year>2014</year>; <volume>113</volume>: <fpage>397</fpage>&#x02013;<lpage>399</lpage>.
2014/03/19. DOI: 10.1016/j.jfma.2014.02.001.<pub-id pub-id-type="pmid">24630489</pub-id></mixed-citation></ref><ref id="bibr59-0300060519845488"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>WC</given-names></name><name><surname>Huang</surname><given-names>WT</given-names></name></person-group>, <etal>et&#x000a0;al.</etal>
<article-title>Surveillance of avian influenza A(H7N9) virus infection in humans
and detection of the first imported human case in Taiwan, 3 April to 10 May
2013</article-title>. <source>Euro Surveill</source>
<year>2013</year>; <volume>18</volume>: pii: <fpage>20479</fpage>.
2013/06/04.<pub-id pub-id-type="pmid">23725865</pub-id></mixed-citation></ref><ref id="bibr60-0300060519845488"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name></person-group>, <etal>et&#x000a0;al.</etal>
<article-title>Spatial and temporal analysis of human infection with avian
influenza A(H7N9) virus in China, 2013</article-title>. <source>Euro
Surveill</source>
<year>2013</year>; <volume>18</volume>: pii: <fpage>20640</fpage>.
2013/12/05.<pub-id pub-id-type="pmid">24300887</pub-id></mixed-citation></ref><ref id="bibr61-0300060519845488"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Cowling</surname><given-names>BJ</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Human infection with avian
influenza A H7N9 virus: an assessment of clinical severity.</article-title>
<source>Lancet</source>
<year>2013</year>; <volume>382</volume>: <fpage>138</fpage>&#x02013;<lpage>145</lpage>.
2013/06/28. DOI: 10.1016/S0140-6736(13)61207-6.<pub-id pub-id-type="pmid">23803487</pub-id></mixed-citation></ref><ref id="bibr62-0300060519845488"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>H7N9: a low pathogenic avian
influenza A virus infecting humans.</article-title>
<source>Curr Opin Virol</source>
<year>2014</year>; <volume>5</volume>: <fpage>91</fpage>&#x02013;<lpage>97</lpage>.
2014/04/08. DOI: 10.1016/j.coviro.2014.03.001.<pub-id pub-id-type="pmid">24705093</pub-id></mixed-citation></ref><ref id="bibr63-0300060519845488"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parry</surname><given-names>J.</given-names></name></person-group>
<article-title>H7N9 avian flu infects humans for the first time.</article-title>
<source>BMJ</source>
<year>2013</year>; <volume>346</volume>: <fpage>f2151</fpage>. DOI:
10.1136/bmj.f2151.<pub-id pub-id-type="pmid">23558347</pub-id></mixed-citation></ref><ref id="bibr64-0300060519845488"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>Y.</given-names></name></person-group>
<article-title>Human infection with H7N9 virus.</article-title>
<source>N Engl J Med</source>
<year>2013</year>; <volume>369</volume>: <fpage>880</fpage>. DOI:
10.1056/NEJMc1308255.</mixed-citation></ref><ref id="bibr65-0300060519845488"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Structures and receptor
binding of hemagglutinins from human-infecting H7N9 influenza
viruses.</article-title>
<source>Science</source>
<year>2013</year>; <volume>342</volume>: <fpage>243</fpage>&#x02013;<lpage>247</lpage>.
DOI: 10.1126/science.1242917.<pub-id pub-id-type="pmid">24009358</pub-id></mixed-citation></ref><ref id="bibr66-0300060519845488"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Martin</surname><given-names>SR</given-names></name><name><surname>Haire</surname><given-names>LF</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Receptor binding by an H7N9
influenza virus from humans.</article-title>
<source>Nature</source>
<year>2013</year>; <volume>499</volume>: <fpage>496</fpage>&#x02013;<lpage>499</lpage>.
2013/06/22. DOI: 10.1038/nature12372.<pub-id pub-id-type="pmid">23787694</pub-id></mixed-citation></ref><ref id="bibr67-0300060519845488"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>An airborne transmissible
avian influenza H5 hemagglutinin seen at the atomic level.</article-title>
<source>Science</source>
<year>2013</year>; <volume>340</volume>:
<fpage>1463</fpage>&#x02013;<lpage>1467</lpage>. DOI:
10.1126/science.1236787.<pub-id pub-id-type="pmid">23641058</pub-id></mixed-citation></ref><ref id="bibr68-0300060519845488"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>X</given-names></name><name><surname>Coombs</surname><given-names>PJ</given-names></name><name><surname>Martin</surname><given-names>SR</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Receptor binding by a
ferret-transmissible H5 avian influenza virus.</article-title>
<source>Nature</source>
<year>2013</year>; <volume>497</volume>: <fpage>392</fpage>&#x02013;<lpage>396</lpage>.
DOI: 10.1038/nature12144.<pub-id pub-id-type="pmid">23615615</pub-id></mixed-citation></ref><ref id="bibr69-0300060519845488"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegers</surname><given-names>JY</given-names></name><name><surname>Short</surname><given-names>KR</given-names></name><name><surname>Leijten</surname><given-names>LM</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Novel avian-origin influenza
A (H7N9) virus attachment to the respiratory tract of five animal
models.</article-title>
<source>J Virol</source>
<year>2014</year>; <volume>88</volume>: <fpage>4595</fpage>&#x02013;<lpage>4599</lpage>.
2014/01/31. DOI: 10.1128/JVI.03190-13.<pub-id pub-id-type="pmid">24478425</pub-id></mixed-citation></ref><ref id="bibr70-0300060519845488"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Kelvin</surname><given-names>DJ</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Infectivity, transmission,
and pathology of human-isolated H7N9 influenza virus in ferrets and
pigs.</article-title>
<source>Science</source>
<year>2013</year>; <volume>341</volume>: <fpage>183</fpage>&#x02013;<lpage>186</lpage>.
2013/05/25. DOI: 10.1126/science.1239844.<pub-id pub-id-type="pmid">23704376</pub-id></mixed-citation></ref><ref id="bibr71-0300060519845488"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Kiso</surname><given-names>M</given-names></name><name><surname>Fukuyama</surname><given-names>S</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Characterization of H7N9
influenza A viruses isolated from humans.</article-title>
<source>Nature</source>
<year>2013</year>; <volume>501</volume>: <fpage>551</fpage>&#x02013;<lpage>555</lpage>.
DOI: 10.1038/nature12392.<pub-id pub-id-type="pmid">23842494</pub-id></mixed-citation></ref><ref id="bibr72-0300060519845488"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>CK</given-names></name><name><surname>Lee</surname><given-names>HH</given-names></name><name><surname>Chan</surname><given-names>MC</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Pathogenicity of the novel
A/H7N9 influenza virus in mice</article-title>. <source>MBio</source>
<year>2013</year>; <volume>4</volume>: pii: <page-range>e00362&#x02013;13</page-range>.
2013/07/04. DOI: 10.1128/mBio.00362-13.</mixed-citation></ref><ref id="bibr73-0300060519845488"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Westward spread of highly
pathogenic avian influenza A(H7N9) virus among humans,
China.</article-title>
<source>Emerg Infect Dis</source>
<year>2018</year>; <volume>24</volume>: <fpage>1095</fpage>&#x02013;<lpage>1098</lpage>.
2018/04/06. DOI: 10.3201/eid2406.171135.<pub-id pub-id-type="pmid">29619922</pub-id></mixed-citation></ref><ref id="bibr74-0300060519845488"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>S</given-names></name><name><surname>Gu</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Epidemiology, evolution, and
pathogenesis of H7N9 influenza viruses in five epidemic waves since 2013 in
China.</article-title>
<source>Trends Microbiol</source>
<year>2017</year>; <volume>25</volume>: <fpage>713</fpage>&#x02013;<lpage>728</lpage>.
2017/07/25. DOI: 10.1016/j.tim.2017.06.008.<pub-id pub-id-type="pmid">28734617</pub-id></mixed-citation></ref><ref id="bibr75-0300060519845488"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Biological characterisation
of the emerged highly pathogenic avian influenza (HPAI) A(H7N9) viruses in
humans, in mainland China, 2016 to 2017</article-title>. <source>Euro
Surveill</source>
<year>2017</year>; <volume>22</volume>: pii: <fpage>30533</fpage>. 2017/05/26.
DOI: 10.2807/1560-7917.ES.2017.22.19.30533.<pub-id pub-id-type="pmid">28537546</pub-id></mixed-citation></ref><ref id="bibr76-0300060519845488"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatta</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>P</given-names></name><name><surname>Halfmann</surname><given-names>P</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Molecular basis for high
virulence of Hong Kong H5N1 influenza A viruses.</article-title>
<source>Science</source>
<year>2001</year>; <volume>293</volume>:
<fpage>1840</fpage>&#x02013;<lpage>1842</lpage>. DOI:
10.1126/science.1062882.<pub-id pub-id-type="pmid">11546875</pub-id></mixed-citation></ref><ref id="bibr77-0300060519845488"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fouchier</surname><given-names>RA</given-names></name><name><surname>Schneeberger</surname><given-names>PM</given-names></name><name><surname>Rozendaal</surname><given-names>FW</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Avian influenza A virus
(H7N7) associated with human conjunctivitis and a fatal case of acute
respiratory distress syndrome.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2004</year>; <volume>101</volume>:
<fpage>1356</fpage>&#x02013;<lpage>1361</lpage>. DOI:
10.1073/pnas.0308352100.<pub-id pub-id-type="pmid">14745020</pub-id></mixed-citation></ref><ref id="bibr78-0300060519845488"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Human infections with the
emerging avian influenza A H7N9 virus from wet market poultry: clinical
analysis and characterisation of viral genome.</article-title>
<source>Lancet</source>
<year>2013</year>; <volume>381</volume>:
<fpage>1916</fpage>&#x02013;<lpage>1925</lpage>. 2013/04/30. DOI:
10.1016/S0140-6736(13)60903-4.<pub-id pub-id-type="pmid">23623390</pub-id></mixed-citation></ref><ref id="bibr79-0300060519845488"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>FY</given-names></name><name><surname>Lin</surname><given-names>TY</given-names></name><name><surname>Chiu</surname><given-names>WT.</given-names></name></person-group>
<article-title>Human infection with H7N9 virus.</article-title>
<source>N Engl J Med</source>
<year>2013</year>; <volume>369</volume>: <fpage>879</fpage>. DOI:
10.1056/NEJMc1308255#SA1.</mixed-citation></ref><ref id="bibr80-0300060519845488"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Human Infection with a novel
avian-origin influenza A (H7N9) virus</article-title>. <source>N Engl J
Med</source>
<year>2013</year>; <volume>368</volume>:
<fpage>1888</fpage>&#x02013;<lpage>1897</lpage>. DOI:
10.1056/NEJMoa1304459.<pub-id pub-id-type="pmid">23577628</pub-id></mixed-citation></ref><ref id="bibr81-0300060519845488"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Horby</surname><given-names>PW</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Comparison of patients
hospitalized with influenza A subtypes H7N9, H5N1, and 2009 pandemic
H1N1.</article-title>
<source>Clin Infect Dis</source>
<year>2014</year>; <volume>58</volume>: <fpage>1095</fpage>&#x02013;<lpage>1103</lpage>.
2014/02/04. DOI: 10.1093/cid/ciu053.<pub-id pub-id-type="pmid">24488975</pub-id></mixed-citation></ref><ref id="bibr82-0300060519845488"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>M</given-names></name><name><surname>Lau</surname><given-names>EHY</given-names></name><name><surname>Guan</surname><given-names>W</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Epidemiology of human
infections with highly pathogenic avian influenza A(H7N9) virus in
Guangdong, 2016 to 2017</article-title>. <source>Euro Surveill</source>
<year>2017</year>; <volume>22</volume>: &#x025aa;. 2017/07/14. DOI:
10.2807/1560-7917.ES.2017.22.27.30568.</mixed-citation></ref><ref id="bibr83-0300060519845488"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>JS</given-names></name><name><surname>Yu</surname><given-names>WC</given-names></name><name><surname>Leung</surname><given-names>CW</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Re-emergence of fatal human
influenza A subtype H5N1 disease.</article-title>
<source>Lancet</source>
<year>2004</year>; <volume>363</volume>: <fpage>617</fpage>&#x02013;<lpage>619</lpage>.
DOI: 10.1016/S0140-6736(04)15595-5.<pub-id pub-id-type="pmid">14987888</pub-id></mixed-citation></ref><ref id="bibr84-0300060519845488"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jong</surname><given-names>MD</given-names></name><name><surname>Simmons</surname><given-names>CP</given-names></name><name><surname>Thanh</surname><given-names>TT</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Fatal outcome of human
influenza A (H5N1) is associated with high viral load and
hypercytokinemia.</article-title>
<source>Nat Med</source>
<year>2006</year>; <volume>12</volume>: <fpage>1203</fpage>&#x02013;<lpage>1207</lpage>.
DOI: 10.1038/nm1477.<pub-id pub-id-type="pmid">16964257</pub-id></mixed-citation></ref><ref id="bibr85-0300060519845488"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>To</surname><given-names>KK</given-names></name><name><surname>Hung</surname><given-names>IF</given-names></name><name><surname>Li</surname><given-names>IW</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Delayed clearance of viral
load and marked cytokine activation in severe cases of pandemic H1N1 2009
influenza virus infection.</article-title>
<source>Clin Infect Dis</source>
<year>2010</year>; <volume>50</volume>: <fpage>850</fpage>&#x02013;<lpage>859</lpage>.
DOI: 10.1086/650581.<pub-id pub-id-type="pmid">20136415</pub-id></mixed-citation></ref><ref id="bibr86-0300060519845488"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>T</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Cytokine and chemokine
levels in patients infected with the novel avian influenza A (H7N9) virus in
China.</article-title>
<source>J Infect Dis</source>
<year>2013</year>; <volume>208</volume>:
<fpage>1962</fpage>&#x02013;<lpage>1967</lpage>. 2013/08/31. DOI:
10.1093/infdis/jit440.<pub-id pub-id-type="pmid">23990573</pub-id></mixed-citation></ref><ref id="bibr87-0300060519845488"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Lou</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Cytokines and chemokines in
mild/asymptomatic cases infected with avian influenza A (H7N9)
virus.</article-title>
<source>J Med Microbiol</source>
<year>2016</year>; <volume>65</volume>: <fpage>1232</fpage>&#x02013;<lpage>1235</lpage>.
2016/08/19. DOI: 10.1099/jmm.0.000333.<pub-id pub-id-type="pmid">27534748</pub-id></mixed-citation></ref><ref id="bibr88-0300060519845488"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Kou</surname><given-names>Z</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Differences in the
pathogenicity and inflammatory responses induced by avian influenza A/H7N9
virus infection in BALB/c and C57BL/6 mouse models.</article-title>
<source>PLoS One</source>
<year>2014</year>; <volume>9</volume>: <fpage>e92987</fpage>. 2014/03/29. DOI:
10.1371/journal.pone.0092987.<pub-id pub-id-type="pmid">24676272</pub-id></mixed-citation></ref><ref id="bibr89-0300060519845488"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zi</surname><given-names>H</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Epidemiological and
molecular characteristics of the PB1-F2 proteins in H7N9 influenza viruses,
Jiangsu.</article-title>
<source>Biomed Res Int</source>
<year>2015</year>; <volume>2015</volume>: <fpage>804731</fpage>. DOI:
10.1155/2015/804731.<pub-id pub-id-type="pmid">25649785</pub-id></mixed-citation></ref><ref id="bibr90-0300060519845488"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eweas</surname><given-names>AF</given-names></name><name><surname>Abdel-Moneim</surname><given-names>AS.</given-names></name></person-group>
<article-title>In-silico structural analysis of the influenza A subtype H7N9
neuraminidase and molecular docking with different neuraminidase
inhibitors.</article-title>
<source>Virusdisease</source>
<year>2015</year>; <volume>26</volume>: <fpage>27</fpage>&#x02013;<lpage>32</lpage>.
2015/10/06. DOI: 10.1007/s13337-014-0245-5.<pub-id pub-id-type="pmid">26436118</pub-id></mixed-citation></ref><ref id="bibr91-0300060519845488"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danqi</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>H7N9 avian influenza A virus
in China: a short report on its circulation, drug resistant mutants and
novel antiviral drugs.</article-title>
<source>Expert Rev Anti Infect Ther</source>
<year>2017</year>; <volume>15</volume>: <fpage>723</fpage>&#x02013;<lpage>727</lpage>.
2017/07/12. DOI: 10.1080/14787210.2017.1353419.<pub-id pub-id-type="pmid">28692316</pub-id></mixed-citation></ref><ref id="bibr92-0300060519845488"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>RY</given-names></name><name><surname>Xiao</surname><given-names>JH</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Inhibition of novel
reassortant avian influenza H7N9 virus infection in vitro with three
antiviral drugs, oseltamivir, peramivir and favipiravir.</article-title>
<source>Antivir Chem Chemother</source>
<year>2014</year>; <volume>23</volume>: <fpage>237</fpage>&#x02013;<lpage>240</lpage>.
2013/08/21. DOI: 10.3851/IMP2672.<pub-id pub-id-type="pmid">23948557</pub-id></mixed-citation></ref><ref id="bibr93-0300060519845488"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Strayer</surname><given-names>DR</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Emergence of a novel drug
resistant H7N9 influenza virus: evidence based clinical potential of a
natural IFN-alpha for infection control and treatment.</article-title>
<source>Expert Rev Anti Infect Ther</source>
<year>2014</year>; <volume>12</volume>: <fpage>165</fpage>&#x02013;<lpage>169</lpage>.
2013/12/20. DOI: 10.1586/14787210.2014.870885.<pub-id pub-id-type="pmid">24350808</pub-id></mixed-citation></ref><ref id="bibr94-0300060519845488"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>HL</given-names></name><name><surname>Herlocher</surname><given-names>LM</given-names></name><name><surname>Hoffmann</surname><given-names>E</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Neuraminidase
inhibitor-resistant influenza viruses may differ substantially in fitness
and transmissibility.</article-title>
<source>Antimicrob Agents Chemother</source>
<year>2005</year>; <volume>49</volume>: <fpage>4075</fpage>&#x02013;<lpage>4084</lpage>.
DOI: 10.1128/AAC.49.10.4075-4084.2005.<pub-id pub-id-type="pmid">16189083</pub-id></mixed-citation></ref><ref id="bibr95-0300060519845488"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>CK</given-names></name><name><surname>Chang</surname><given-names>SC</given-names></name><name><surname>Chen</surname><given-names>GW</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Pyrosequencing reveals an
oseltamivir-resistant marker in the quasispecies of avian influenza A (H7N9)
virus.</article-title>
<source>J Microbiol Immunol Infect</source>
<year>2015</year>; <volume>48</volume>: <fpage>465</fpage>&#x02013;<lpage>469</lpage>.
2014/01/07. DOI: 10.1016/j.jmii.2013.09.010.<pub-id pub-id-type="pmid">24388586</pub-id></mixed-citation></ref><ref id="bibr96-0300060519845488"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marjuki</surname><given-names>H</given-names></name><name><surname>Mishin</surname><given-names>VP</given-names></name><name><surname>Chesnokov</surname><given-names>AP</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Characterization of
drug-resistant influenza A(H7N9) variants isolated from an
oseltamivir&#x02013;treated patient in Taiwan.</article-title>
<source>J Infect Dis</source>
<year>2015</year>; <volume>211</volume>: <fpage>249</fpage>&#x02013;<lpage>257</lpage>.
2014/08/16. DOI: 10.1093/infdis/jiu447.<pub-id pub-id-type="pmid">25124927</pub-id></mixed-citation></ref><ref id="bibr97-0300060519845488"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hai</surname><given-names>R</given-names></name><name><surname>Schmolke</surname><given-names>M</given-names></name><name><surname>Leyva-Grado</surname><given-names>VH</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Influenza A(H7N9) virus
gains neuraminidase inhibitor resistance without loss of in vivo virulence
or transmissibility.</article-title>
<source>Nat Commun</source>
<year>2013</year>; <volume>4</volume>: <fpage>2854</fpage>. 2013/12/12. DOI:
10.1038/ncomms3854.<pub-id pub-id-type="pmid">24326875</pub-id></mixed-citation></ref><ref id="bibr98-0300060519845488"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Wong</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Ribavirin is effective
against drug-resistant H7N9 influenza virus infections.</article-title>
<source>Protein Cell</source>
<year>2016</year>; <volume>7</volume>: <fpage>611</fpage>&#x02013;<lpage>614</lpage>.
2016/07/20. DOI: 10.1007/s13238-016-0287-0.<pub-id pub-id-type="pmid">27430950</pub-id></mixed-citation></ref><ref id="bibr99-0300060519845488"><label>99</label><mixed-citation publication-type="book"><collab>XOFLUZA</collab> (Baloxavir
marboxil) for the treatment of influenza types A and B launched in Japan.
<italic>Shionogi press release</italic>
<year>2018</year>.</mixed-citation></ref><ref id="bibr100-0300060519845488"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Gu</surname><given-names>C</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>A live attenuated vaccine
prevents replication and transmission of H7N9 virus in
mammals.</article-title>
<source>Sci Rep</source>
<year>2015</year>; <volume>5</volume>: <fpage>11233</fpage>. 2015/06/11. DOI:
10.1038/srep11233.<pub-id pub-id-type="pmid">26058711</pub-id></mixed-citation></ref><ref id="bibr101-0300060519845488"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chia</surname><given-names>MY</given-names></name><name><surname>Hu</surname><given-names>AY</given-names></name><name><surname>Tseng</surname><given-names>YF</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Evaluation of MDCK
cell-derived influenza H7N9 vaccine candidates in ferrets.</article-title>
<source>PLoS One</source>
<year>2015</year>; <volume>10</volume>: <fpage>e0120793</fpage>. 2015/03/24.
DOI: 10.1371/journal.pone.0120793.<pub-id pub-id-type="pmid">25799397</pub-id></mixed-citation></ref><ref id="bibr102-0300060519845488"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wodal</surname><given-names>W</given-names></name><name><surname>Schwendinger</surname><given-names>MG</given-names></name><name><surname>Savidis-Dacho</surname><given-names>H</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Immunogenicity and
protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine
in mice and guinea pigs.</article-title>
<source>PLoS One</source>
<year>2015</year>; <volume>10</volume>: <fpage>e0113963</fpage>. 2015/02/27.
DOI: 10.1371/journal.pone.0113963.<pub-id pub-id-type="pmid">25719901</pub-id></mixed-citation></ref><ref id="bibr103-0300060519845488"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>[Safety and immunogenicity
of seasonal inactivated influenza vaccine (split virion) and cross-reactive
antibody responses to the H7N9 avian influenza virus].</article-title>
<source>Zhonghua Liu Xing Bing Xue Za Zhi</source>
<year>2014</year>; <volume>35</volume>: <fpage>949</fpage>&#x02013;<lpage>952</lpage>.
2014/11/08.<pub-id pub-id-type="pmid">25376689</pub-id></mixed-citation></ref><ref id="bibr104-0300060519845488"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Villarreal</surname><given-names>DO</given-names></name><name><surname>Racine</surname><given-names>T</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Protective immunity to H7N9
influenza viruses elicited by synthetic DNA vaccine.</article-title>
<source>Vaccine</source>
<year>2014</year>; <volume>32</volume>: <fpage>2833</fpage>&#x02013;<lpage>2842</lpage>.
2014/03/19. DOI: 10.1016/j.vaccine.2014.02.038.<pub-id pub-id-type="pmid">24631084</pub-id></mixed-citation></ref><ref id="bibr105-0300060519845488"><label>105</label><mixed-citation publication-type="other"><collab>Novavax' H7N9 avian influenza VLP
vaccine positive in Phase 1/2.</collab>
<italic>Hum Vaccin Immunother</italic>
<year>2014</year>; 10: 3103&#x02013;3104. 2014/01/01.</mixed-citation></ref><ref id="bibr106-0300060519845488"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fries</surname><given-names>LF</given-names></name><name><surname>Smith</surname><given-names>GE</given-names></name><name><surname>Glenn</surname><given-names>GM.</given-names></name></person-group>
<article-title>A recombinant viruslike particle influenza A (H7N9)
vaccine.</article-title>
<source>N Engl J Med</source>
<year>2013</year>; <volume>369</volume>:
<fpage>2564</fpage>&#x02013;<lpage>2566</lpage>. 2013/11/15. DOI:
10.1056/NEJMc1313186.</mixed-citation></ref><ref id="bibr107-0300060519845488"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>GE</given-names></name><name><surname>Flyer</surname><given-names>DC</given-names></name><name><surname>Raghunandan</surname><given-names>R</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Development of influenza
H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9)
protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3)
cross-protection in vaccinated mice challenged with H7N9
virus.</article-title>
<source>Vaccine</source>
<year>2013</year>; <volume>31</volume>: <fpage>4305</fpage>&#x02013;<lpage>4313</lpage>.
2013/07/31. DOI: 10.1016/j.vaccine.2013.07.043.<pub-id pub-id-type="pmid">23891795</pub-id></mixed-citation></ref><ref id="bibr108-0300060519845488"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isakova-Sivak</surname><given-names>I</given-names></name><name><surname>Rudenko</surname><given-names>L.</given-names></name></person-group>
<article-title>Tackling a novel lethal virus: a focus on H7N9 vaccine
development.</article-title>
<source>Expert Rev Vaccines</source>
<year>2017</year>; <volume>16</volume>: <fpage>1</fpage>&#x02013;<lpage>13</lpage>.
2017/05/24. DOI: 10.1080/14760584.2017.1333907.</mixed-citation></ref><ref id="bibr109-0300060519845488"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridenour</surname><given-names>C</given-names></name><name><surname>Johnson</surname><given-names>A</given-names></name><name><surname>Winne</surname><given-names>E</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Development of influenza
A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield
in eggs.</article-title>
<source>Influenza Other Respir Viruses</source>
<year>2015</year>; <volume>9</volume>: <fpage>263</fpage>&#x02013;<lpage>270</lpage>.
2015/05/13. DOI: 10.1111/irv.12322.<pub-id pub-id-type="pmid">25962412</pub-id></mixed-citation></ref><ref id="bibr110-0300060519845488"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobhanie</surname><given-names>M</given-names></name><name><surname>Matsuoka</surname><given-names>Y</given-names></name><name><surname>Jegaskanda</surname><given-names>S</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Evaluation of the safety and
immunogenicity of a candidate pandemic live attenuated influenza vaccine
(pLAIV) against influenza A(H7N9).</article-title>
<source>J Infect Dis</source>
<year>2016</year>; <volume>213</volume>: <fpage>922</fpage>&#x02013;<lpage>929</lpage>.
2015/12/15. DOI: 10.1093/infdis/jiv526.<pub-id pub-id-type="pmid">26655841</pub-id></mixed-citation></ref><ref id="bibr111-0300060519845488"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudenko</surname><given-names>L</given-names></name><name><surname>Isakova-Sivak</surname><given-names>I</given-names></name><name><surname>Naykhin</surname><given-names>A</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>H7N9 live attenuated
influenza vaccine in healthy adults: a randomised, double-blind,
placebo-controlled, phase 1 trial.</article-title>
<source>Lancet Infect Dis</source>
<year>2016</year>; <volume>16</volume>: <fpage>303</fpage>&#x02013;<lpage>310</lpage>.
2015/12/18. DOI: 10.1016/S1473-3099(15)00378-3.<pub-id pub-id-type="pmid">26673391</pub-id></mixed-citation></ref><ref id="bibr112-0300060519845488"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudenko</surname><given-names>L</given-names></name><name><surname>Kiseleva</surname><given-names>I</given-names></name><name><surname>Naykhin</surname><given-names>AN</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Assessment of human immune
responses to H7 avian influenza virus of pandemic potential: results from a
placebo-controlled, randomized double-blind phase I study of live attenuated
H7N3 influenza vaccine.</article-title>
<source>PLoS One</source>
<year>2014</year>; <volume>9</volume>: <fpage>e87962</fpage>. 2014/02/18. DOI:
10.1371/journal.pone.0087962.<pub-id pub-id-type="pmid">24533064</pub-id></mixed-citation></ref><ref id="bibr113-0300060519845488"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudenko</surname><given-names>L</given-names></name><name><surname>Desheva</surname><given-names>J</given-names></name><name><surname>Korovkin</surname><given-names>S</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Safety and immunogenicity of
live attenuated influenza reassortant H5 vaccine (phase I-II clinical
trials).</article-title>
<source>Influenza Other Respir Viruses</source>
<year>2008</year>; <volume>2</volume>: <fpage>203</fpage>&#x02013;<lpage>209</lpage>.
DOI: 10.1111/j.1750-2659.2008.00064.x.<pub-id pub-id-type="pmid">19453396</pub-id></mixed-citation></ref><ref id="bibr114-0300060519845488"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talaat</surname><given-names>KR</given-names></name><name><surname>Karron</surname><given-names>RA</given-names></name><name><surname>Callahan</surname><given-names>KA</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>A live attenuated H7N3
influenza virus vaccine is well tolerated and immunogenic in a Phase I trial
in healthy adults.</article-title>
<source>Vaccine</source>
<year>2009</year>; <volume>27</volume>: <fpage>3744</fpage>&#x02013;<lpage>3753</lpage>.
DOI: 10.1016/j.vaccine.2009.03.082.<pub-id pub-id-type="pmid">19464558</pub-id></mixed-citation></ref><ref id="bibr115-0300060519845488"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudenko</surname><given-names>L</given-names></name><name><surname>Isakova-Sivak</surname><given-names>I</given-names></name><name><surname>Donina</surname><given-names>S.</given-names></name></person-group>
<article-title>H7N3 live attenuated influenza vaccine has a potential to protect
against new H7N9 avian influenza virus.</article-title>
<source>Vaccine</source>
<year>2013</year>; <volume>31</volume>: <fpage>4702</fpage>&#x02013;<lpage>4705</lpage>.
2013/08/31. DOI: 10.1016/j.vaccine.2013.08.040.<pub-id pub-id-type="pmid">23988294</pub-id></mixed-citation></ref><ref id="bibr116-0300060519845488"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>DM</given-names></name><name><surname>Bloom</surname><given-names>CE</given-names></name><name><surname>Kirchenbaum</surname><given-names>GA</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Cross-protection against
H7N9 influenza strains using a live-attenuated H7N3 virus
vaccine.</article-title>
<source>Vaccine</source>
<year>2015</year>; <volume>33</volume>: <fpage>108</fpage>&#x02013;<lpage>116</lpage>.
2014/12/03. DOI: 10.1016/j.vaccine.2014.11.008.<pub-id pub-id-type="pmid">25448100</pub-id></mixed-citation></ref><ref id="bibr117-0300060519845488"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couch</surname><given-names>RB</given-names></name><name><surname>Patel</surname><given-names>SM</given-names></name><name><surname>Wade-Bowers</surname><given-names>CL</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>A randomized clinical trial
of an inactivated avian influenza A (H7N7) vaccine.</article-title>
<source>PLoS One</source>
<year>2012</year>; <volume>7</volume>: <fpage>e49704</fpage>. DOI:
10.1371/journal.pone.0049704.<pub-id pub-id-type="pmid">23239968</pub-id></mixed-citation></ref><ref id="bibr118-0300060519845488"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>RJ</given-names></name><name><surname>Major</surname><given-names>D</given-names></name><name><surname>Hauge</surname><given-names>S</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>A cell-based H7N1 split
influenza virion vaccine confers protection in mouse and ferret challenge
models.</article-title>
<source>Influenza Other Respir Viruses</source>
<year>2009</year>; <volume>3</volume>: <fpage>107</fpage>&#x02013;<lpage>117</lpage>.
DOI: 10.1111/j.1750-2659.2009.00082.x.<pub-id pub-id-type="pmid">19453487</pub-id></mixed-citation></ref><ref id="bibr119-0300060519845488"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madan</surname><given-names>A</given-names></name><name><surname>Segall</surname><given-names>N</given-names></name><name><surname>Ferguson</surname><given-names>M</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Immunogenicity and safety of
an AS03-Adjuvanted H7N9 pandemic influenza vaccine in a randomized trial in
healthy adults.</article-title>
<source>J Infect Dis</source>
<year>2016</year>; <volume>214</volume>:
<fpage>1717</fpage>&#x02013;<lpage>1727</lpage>. 2016/09/10. DOI:
10.1093/infdis/jiw414.<pub-id pub-id-type="pmid">27609809</pub-id></mixed-citation></ref><ref id="bibr120-0300060519845488"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishiura</surname><given-names>H</given-names></name><name><surname>Mizumoto</surname><given-names>K</given-names></name><name><surname>Ejima</surname><given-names>K.</given-names></name></person-group>
<article-title>How to interpret the transmissibility of novel influenza A(H7N9):
an analysis of initial epidemiological data of human cases from
China.</article-title>
<source>Theor Biol Med Model</source>
<year>2013</year>; <volume>10</volume>: <fpage>30</fpage>. 2013/05/07. DOI:
10.1186/1742-4682-10-30.<pub-id pub-id-type="pmid">23642092</pub-id></mixed-citation></ref><ref id="bibr121-0300060519845488"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J.</given-names></name></person-group>
<article-title>An update on clinical trials of H7N9 influenza
vaccines.</article-title>
<source>J Appl Virol</source>
<year>2014</year>; <volume>3</volume>: &#x025aa;. DOI: <pub-id pub-id-type="doi">10.21092/jav.v3i3.37</pub-id>.</mixed-citation></ref><ref id="bibr122-0300060519845488"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Recombinant baculovirus
vaccine expressing hemagglutinin of H7N9 avian influenza virus confers full
protection against lethal highly pathogenic H7N9 virus infection in
chickens</article-title>. <source>Arch Virol</source>
<year>2019</year>; <volume>164</volume>: <fpage>807</fpage>&#x02013;<lpage>817</lpage>.
2019/01/24. DOI: 10.1007/s00705-018-04142-4.<pub-id pub-id-type="pmid">30671655</pub-id></mixed-citation></ref><ref id="bibr123-0300060519845488"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>DH</given-names></name><name><surname>Sakoda</surname><given-names>Y</given-names></name><name><surname>Nishi</surname><given-names>T</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Potency of an inactivated
influenza vaccine prepared from A/duck/Mongolia/119/2008 (H7N9) against the
challenge with A/Anhui/1/2013 (H7N9).</article-title>
<source>Vaccine</source>
<year>2014</year>; <volume>32</volume>: <fpage>3473</fpage>&#x02013;<lpage>3479</lpage>.
2014/05/06. DOI: 10.1016/j.vaccine.2014.04.060.<pub-id pub-id-type="pmid">24793949</pub-id></mixed-citation></ref><ref id="bibr124-0300060519845488"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Ke</surname><given-names>C</given-names></name><name><surname>Lau</surname><given-names>EHY</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Influenza H5/H7 virus
vaccination in poultry and reduction of zoonotic infections, Guangdong
Province, China, 2017-18.</article-title>
<source>Emerg Infect Dis</source>
<year>2019</year>; <volume>25</volume>: <fpage>116</fpage>&#x02013;<lpage>118</lpage>.
2018/10/26. DOI: 10.3201/eid2501.181259.<pub-id pub-id-type="pmid">30355435</pub-id></mixed-citation></ref><ref id="bibr125-0300060519845488"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Hou</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Influenza viral vectors
expressing two kinds of HA proteins as bivalent vaccine against highly
pathogenic avian influenza viruses of clade 2.3.4.4 H5 and
H7N9.</article-title>
<source>Front Microbiol</source>
<year>2018</year>; <volume>9</volume>: <fpage>604</fpage>. 2018/04/20. DOI:
10.3389/fmicb.2018.00604.<pub-id pub-id-type="pmid">29670587</pub-id></mixed-citation></ref><ref id="bibr126-0300060519845488"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Tian</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Vaccination of poultry
successfully eliminated human infection with H7N9 virus in
China.</article-title>
<source>Sci China Life Sci</source>
<year>2018</year>; <volume>61</volume>: <fpage>1465</fpage>&#x02013;<lpage>1473</lpage>.
2018/11/11. DOI: 10.1007/s11427-018-9420-1.<pub-id pub-id-type="pmid">30414008</pub-id></mixed-citation></ref><ref id="bibr127-0300060519845488"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>G</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Rapid evolution of H7N9
highly pathogenic viruses that emerged in China in 2017.</article-title>
<source>Cell Host Microbe</source>
<year>2018</year>; <volume>24</volume>:
<fpage>558</fpage>&#x02013;<lpage>568</lpage>.e7. 2018/10/03. DOI:
10.1016/j.chom.2018.08.006.<pub-id pub-id-type="pmid">30269969</pub-id></mixed-citation></ref><ref id="bibr128-0300060519845488"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okamatsu</surname><given-names>M</given-names></name><name><surname>Hiono</surname><given-names>T</given-names></name><name><surname>Kida</surname><given-names>H</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Recent developments in the
diagnosis of avian influenza.</article-title>
<source>Vet J</source>
<year>2016</year>; <volume>215</volume>: <fpage>82</fpage>&#x02013;<lpage>86</lpage>.
DOI: 10.1016/j.tvjl.2016.05.007.<pub-id pub-id-type="pmid">27241842</pub-id></mixed-citation></ref><ref id="bibr129-0300060519845488"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spackman</surname><given-names>E</given-names></name><name><surname>Killian</surname><given-names>ML.</given-names></name></person-group>
<article-title>Avian influenza virus isolation, propagation, and titration in
embryonated chicken eggs</article-title>. <source>Methods Mol Biol</source>
<year>2014</year>; <volume>1161</volume>: <fpage>125</fpage>&#x02013;<lpage>140</lpage>.
DOI: 10.1007/978-1-4939-0758-8_12.<pub-id pub-id-type="pmid">24899426</pub-id></mixed-citation></ref><ref id="bibr130-0300060519845488"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Ni</surname><given-names>X</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Laboratory diagnosis and
epidemiology of avian influenza A (H7N9) virus infection in humans in
Nanchang City, China.</article-title>
<source>Jpn J Infect Dis</source>
<year>2013</year>; <volume>66</volume>: <fpage>558</fpage>&#x02013;<lpage>560</lpage>.
2013/11/26.<pub-id pub-id-type="pmid">24270153</pub-id></mixed-citation></ref><ref id="bibr131-0300060519845488"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Rapid diagnostic tests for
identifying avian influenza A(H7N9) virus in clinical
samples</article-title>. <source>Emerg Infect Dis</source>
<year>2015</year>; <volume>21</volume>: <fpage>87</fpage>&#x02013;<lpage>90</lpage>.
2014/12/23. DOI: 10.3201/eid2101.140247.<pub-id pub-id-type="pmid">25529064</pub-id></mixed-citation></ref><ref id="bibr132-0300060519845488"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vemula</surname><given-names>SV</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Current approaches for
diagnosis of influenza virus infections in humans.</article-title>
<source>Viruses</source>
<year>2016</year>; <volume>8</volume>: <fpage>96</fpage>. DOI:
10.3390/v8040096.<pub-id pub-id-type="pmid">27077877</pub-id></mixed-citation></ref><ref id="bibr133-0300060519845488"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Cross-reactivity between
avian influenza A (H7N9) virus and divergent H7 subtypic- and heterosubtypic
influenza A viruses.</article-title>
<source>Sci Rep</source>
<year>2016</year>; <volume>6</volume>: <fpage>22045</fpage>. 2016/02/26. DOI:
10.1038/srep22045.<pub-id pub-id-type="pmid">26907865</pub-id></mixed-citation></ref><ref id="bibr134-0300060519845488"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>J.</given-names></name></person-group>
<article-title>The critical need for rapid influenza serology testing for avian
influenza pandemic preparedness.</article-title>
<source>Health Secur</source>
<year>2017</year>; <volume>15</volume>: <fpage>450</fpage>&#x02013;<lpage>451</lpage>.
DOI: 10.1089/hs.2017.0041.<pub-id pub-id-type="pmid">28805466</pub-id></mixed-citation></ref><ref id="bibr135-0300060519845488"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>JC.</given-names></name></person-group>
<article-title>Hemagglutination-inhibition assay for influenza virus subtype
identification and the detection and quantitation of serum antibodies to
influenza virus</article-title>. <source>Methods Mol Biol</source>
<year>2014</year>; <volume>1161</volume>: <fpage>11</fpage>&#x02013;<lpage>25</lpage>.
DOI: 10.1007/978-1-4939-0758-8_2.<pub-id pub-id-type="pmid">24899416</pub-id></mixed-citation></ref><ref id="bibr136-0300060519845488"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trombetta</surname><given-names>CM</given-names></name><name><surname>Remarque</surname><given-names>EJ</given-names></name><name><surname>Mortier</surname><given-names>D</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Comparison of
hemagglutination inhibition, single radial hemolysis, virus neutralization
assays, and ELISA to detect antibody levels against seasonal influenza
viruses.</article-title>
<source>Influenza Other Respir Viruses</source>
<year>2018</year>; <volume>12</volume>: <fpage>675</fpage>&#x02013;<lpage>686</lpage>.
DOI: 10.1111/irv.12591.<pub-id pub-id-type="pmid">30019448</pub-id></mixed-citation></ref><ref id="bibr137-0300060519845488"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Russell</surname><given-names>ML</given-names></name><name><surname>Brewer</surname><given-names>A</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Single radial haemolysis
compared to haemagglutinin inhibition and microneutralization as a correlate
of protection against influenza A H3N2 in children and
adolescents.</article-title>
<source>Influenza Other Respir Viruses</source>
<year>2017</year>; <volume>11</volume>: <fpage>283</fpage>&#x02013;<lpage>288</lpage>.
DOI: 10.1111/irv.12450.<pub-id pub-id-type="pmid">28218983</pub-id></mixed-citation></ref><ref id="bibr138-0300060519845488"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teferedegne</surname><given-names>B</given-names></name><name><surname>Lewis</surname><given-names>AM</given-names><suffix>Jr</suffix></name><name><surname>Peden</surname><given-names>K</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Development of a
neutralization assay for influenza virus using an endpoint assessment based
on quantitative reverse-transcription PCR.</article-title>
<source>PLoS One</source>
<year>2013</year>; <volume>8</volume>: <fpage>e56023</fpage>. DOI:
10.1371/journal.pone.0056023.<pub-id pub-id-type="pmid">23437084</pub-id></mixed-citation></ref><ref id="bibr139-0300060519845488"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Fang</surname><given-names>C</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Versatile microfluidic
complement fixation test for disease biomarker detection.</article-title>
<source>Anal Chim Acta</source>
<year>2016</year>; <volume>916</volume>: <fpage>67</fpage>&#x02013;<lpage>76</lpage>.
DOI: 10.1016/j.aca.2016.02.026.<pub-id pub-id-type="pmid">27016440</pub-id></mixed-citation></ref><ref id="bibr140-0300060519845488"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>KC</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Interpreting the
transmissibility of the avian influenza A(H7N9) infection from 2013 to 2015
in Zhejiang Province, China.</article-title>
<source>Epidemiol Infect</source>
<year>2016</year>; <volume>144</volume>:
<fpage>1584</fpage>&#x02013;<lpage>1591</lpage>. 2015/12/10. DOI:
10.1017/S0950268815002812.<pub-id pub-id-type="pmid">26645357</pub-id></mixed-citation></ref><ref id="bibr141-0300060519845488"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trombetta</surname><given-names>CM</given-names></name><name><surname>Perini</surname><given-names>D</given-names></name><name><surname>Vitale</surname><given-names>L</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Validation of single radial
haemolysis assay: a reliable method to measure antibodies against influenza
viruses.</article-title>
<source>J Immunol Methods</source>
<year>2015</year>; <volume>422</volume>: <fpage>95</fpage>&#x02013;<lpage>101</lpage>.
DOI: 10.1016/j.jim.2015.04.009.<pub-id pub-id-type="pmid">25910832</pub-id></mixed-citation></ref><ref id="bibr142-0300060519845488"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Jiao</surname><given-names>P</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>An impedance immunosensor
based on low-cost microelectrodes and specific monoclonal antibodies for
rapid detection of avian influenza virus H5N1 in chicken
swabs.</article-title>
<source>Biosens Bioelectron</source>
<year>2015</year>; <volume>67</volume>: <fpage>546</fpage>&#x02013;<lpage>552</lpage>.
DOI: 10.1016/j.bios.2014.09.037.<pub-id pub-id-type="pmid">25263315</pub-id></mixed-citation></ref><ref id="bibr143-0300060519845488"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bucukovski</surname><given-names>J</given-names></name><name><surname>Latorre-Margalef</surname><given-names>N</given-names></name><name><surname>Stallknecht</surname><given-names>DE</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>A multiplex label-free
approach to avian influenza surveillance and serology.</article-title>
<source>PLoS One</source>
<year>2015</year>; <volume>10</volume>: <fpage>e0134484</fpage>. DOI:
10.1371/journal.pone.0134484.<pub-id pub-id-type="pmid">26241048</pub-id></mixed-citation></ref><ref id="bibr144-0300060519845488"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grund</surname><given-names>S</given-names></name><name><surname>Adams</surname><given-names>O</given-names></name><name><surname>Wahlisch</surname><given-names>S</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Comparison of
hemagglutination inhibition assay, an ELISA-based micro-neutralization assay
and colorimetric microneutralization assay to detect antibody responses to
vaccination against influenza A H1N1 2009 virus.</article-title>
<source>J Virol Methods</source>
<year>2011</year>; <volume>171</volume>: <fpage>369</fpage>&#x02013;<lpage>373</lpage>.
DOI: 10.1016/j.jviromet.2010.11.024.<pub-id pub-id-type="pmid">21146560</pub-id></mixed-citation></ref><ref id="bibr145-0300060519845488"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>G</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Automated interpretation of
influenza hemagglutination inhibition (HAI) assays: is plate tilting
necessary?</article-title>
<source>PLoS One</source>
<year>2017</year>; <volume>12</volume>: <fpage>e0179939</fpage>. DOI:
10.1371/journal.pone.0179939.<pub-id pub-id-type="pmid">28662088</pub-id></mixed-citation></ref><ref id="bibr146-0300060519845488"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YF</given-names></name><name><surname>Xie</surname><given-names>ZX</given-names></name><name><surname>Xie</surname><given-names>LJ</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>GeXP analyzer-based
multiplex reverse-transcription PCR assay for the simultaneous detection and
differentiation of eleven duck viruses.</article-title>
<source>BMC Microbiol</source>
<year>2015</year>; <volume>15</volume>: <fpage>247</fpage>. 2015/11/01. DOI:
10.1186/s12866-015-0590-6.<pub-id pub-id-type="pmid">26518004</pub-id></mixed-citation></ref><ref id="bibr147-0300060519845488"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Simultaneous detection of
eight avian influenza A virus subtypes by multiplex reverse
transcription-PCR using a GeXP analyser.</article-title>
<source>Sci Rep</source>
<year>2018</year>; <volume>8</volume>: <fpage>6183</fpage>. 2018/04/20. DOI:
10.1038/s41598-018-24620-8.<pub-id pub-id-type="pmid">29670227</pub-id></mixed-citation></ref><ref id="bibr148-0300060519845488"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Simultaneous detection of
four different neuraminidase types of avian influenza A H5 viruses by
multiplex reverse transcription PCR using a GeXP analyser.</article-title>
<source>Influenza Other Respir Viruses</source>
<year>2016</year>; <volume>10</volume>: <fpage>141</fpage>&#x02013;<lpage>149</lpage>.
DOI: 10.1111/irv.12370.<pub-id pub-id-type="pmid">26677838</pub-id></mixed-citation></ref><ref id="bibr149-0300060519845488"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virlogeux</surname><given-names>V</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Tsang</surname><given-names>TK</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Evaluation of
animal-to-human and human-to-human transmission of influenza A (H7N9) virus
in China, 2013-15.</article-title>
<source>Sci Rep</source>
<year>2018</year>; <volume>8</volume>: <fpage>552</fpage>. 2018/01/13. DOI:
10.1038/s41598-017-17335-9.<pub-id pub-id-type="pmid">29323268</pub-id></mixed-citation></ref><ref id="bibr150-0300060519845488"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chowell</surname><given-names>G</given-names></name><name><surname>Simonsen</surname><given-names>L</given-names></name><name><surname>Towers</surname><given-names>S</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Transmission potential of
influenza A/H7N9, February to May 2013, China.</article-title>
<source>BMC Med</source>
<year>2013</year>; <volume>11</volume>: <fpage>214</fpage>. 2013/10/03. DOI:
10.1186/1741-7015-11-214.<pub-id pub-id-type="pmid">24083506</pub-id></mixed-citation></ref><ref id="bibr151-0300060519845488"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name></person-group>
<article-title>Much higher case-fatality rates of index cases. commentary:
differences in the epidemiology of human cases of avian influenza A(H7N9)
and A(H5N1) viruses infection.</article-title>
<source>Front Public Health</source>
<year>2016</year>; <volume>4</volume>: <fpage>116</fpage>. 2016/07/06. DOI:
10.3389/fpubh.2016.00116.<pub-id pub-id-type="pmid">27378438</pub-id></mixed-citation></ref><ref id="bibr152-0300060519845488"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meliopoulos</surname><given-names>VA</given-names></name><name><surname>Karlsson</surname><given-names>EA</given-names></name><name><surname>Kercher</surname><given-names>L</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Human H7N9 and H5N1
influenza viruses differ in induction of cytokines and tissue
tropism.</article-title>
<source>J Virol</source>
<year>2014</year>; <volume>88</volume>:
<fpage>12982</fpage>&#x02013;<lpage>12991</lpage>. 2014/09/12. DOI:
10.1128/JVI.01571-14.<pub-id pub-id-type="pmid">25210188</pub-id></mixed-citation></ref><ref id="bibr153-0300060519845488"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>HN</given-names></name><name><surname>Lu</surname><given-names>HZ</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Clinical findings in 111
cases of influenza A (H7N9) virus infection.</article-title>
<source>N Engl J Med</source>
<year>2013</year>; <volume>368</volume>:
<fpage>2277</fpage>&#x02013;<lpage>2285</lpage>. 2013/05/24. DOI:
10.1056/NEJMoa1305584.<pub-id pub-id-type="pmid">23697469</pub-id></mixed-citation></ref><ref id="bibr154-0300060519845488"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>Z</given-names></name><name><surname>Lv</surname><given-names>H</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Comparison of
characteristics between patients with H7N9 living in rural and urban areas
of Zhejiang Province, China: a preliminary report.</article-title>
<source>PLoS One</source>
<year>2014</year>; <volume>9</volume>: <fpage>e93775</fpage>. 2014/04/09. DOI:
10.1371/journal.pone.0093775.<pub-id pub-id-type="pmid">24710171</pub-id></mixed-citation></ref><ref id="bibr155-0300060519845488"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Biological features of novel
avian influenza A (H7N9) virus.</article-title>
<source>Nature</source>
<year>2013</year>; <volume>499</volume>: <fpage>500</fpage>&#x02013;<lpage>503</lpage>.
2013/07/05. DOI: 10.1038/nature12379.<pub-id pub-id-type="pmid">23823727</pub-id></mixed-citation></ref><ref id="bibr156-0300060519845488"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>MH</given-names></name><name><surname>He</surname><given-names>F</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>An increasing trend of rural
infections of human influenza A (H7N9) from 2013 to 2017: a retrospective
analysis of patient exposure histories in Zhejiang Province,
China.</article-title>
<source>PLoS One</source>
<year>2018</year>; <volume>13</volume>: <fpage>e0193052</fpage>. 2018/02/16.
DOI: 10.1371/journal.pone.0193052.<pub-id pub-id-type="pmid">29447278</pub-id></mixed-citation></ref><ref id="bibr157-0300060519845488"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>PH</given-names></name><name><surname>Chao</surname><given-names>TL</given-names></name><name><surname>Kuo</surname><given-names>SW</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Virological, serological,
and antiviral studies in an imported human case of avian influenza A(H7N9)
virus in Taiwan.</article-title>
<source>Clin Infect Dis</source>
<year>2014</year>; <volume>58</volume>: <fpage>242</fpage>&#x02013;<lpage>246</lpage>.
2013/10/01. DOI: 10.1093/cid/cit638.<pub-id pub-id-type="pmid">24076969</pub-id></mixed-citation></ref><ref id="bibr158-0300060519845488"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>ACY</given-names></name><name><surname>To</surname><given-names>KKW</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Avian influenza virus A H7N9
infects multiple mononuclear cell types in peripheral blood and induces
dysregulated cytokine responses and apoptosis in infected
monocytes.</article-title>
<source>J Gen Virol</source>
<year>2017</year>; <volume>98</volume>: <fpage>922</fpage>&#x02013;<lpage>934</lpage>.
2017/05/31. DOI: 10.1099/jgv.0.000751.<pub-id pub-id-type="pmid">28555541</pub-id></mixed-citation></ref><ref id="bibr159-0300060519845488"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>A</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Early hypercytokinemia is
associated with interferon-induced transmembrane protein-3 dysfunction and
predictive of fatal H7N9 infection.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2014</year>; <volume>111</volume>: <fpage>769</fpage>&#x02013;<lpage>774</lpage>.
2013/12/25. DOI: 10.1073/pnas.1321748111.<pub-id pub-id-type="pmid">24367104</pub-id></mixed-citation></ref><ref id="bibr160-0300060519845488"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>The mouse and ferret models
for studying the novel avian-origin human influenza A (H7N9)
virus.</article-title>
<source>Virol J</source>
<year>2013</year>; <volume>10</volume>: <fpage>253</fpage>. 2013/08/10. DOI:
10.1186/1743-422X-10-253.<pub-id pub-id-type="pmid">23927489</pub-id></mixed-citation></ref><ref id="bibr161-0300060519845488"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gubareva</surname><given-names>LV</given-names></name><name><surname>Sleeman</surname><given-names>K</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Drug susceptibility
evaluation of an influenza A (H7N9) virus by analyzing recombinant
neuraminidase proteins.</article-title>
<source>J Infect Dis</source>
<year>2017</year>; <volume>216</volume>:
<fpage>S566</fpage>&#x02013;<lpage>S574</lpage>. 2017/09/22. DOI:
10.1093/infdis/jiw625.<pub-id pub-id-type="pmid">28934455</pub-id></mixed-citation></ref><ref id="bibr162-0300060519845488"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>FS</given-names></name><name><surname>Lee</surname><given-names>YT</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Progress in developing
virus-like particle influenza vaccines.</article-title>
<source>Expert Rev Vaccines</source>
<year>2016</year>; <volume>15</volume>: <fpage>1281</fpage>&#x02013;<lpage>1293</lpage>.
2016/04/09. DOI: 10.1080/14760584.2016.1175942.<pub-id pub-id-type="pmid">27058302</pub-id></mixed-citation></ref><ref id="bibr163-0300060519845488"><label>163</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Development of rapid
immunochromatographic test for hemagglutinin antigen of H7 subtype in
patients infected with novel avian influenza A (H7N9) virus.</article-title>
<source>PLoS One</source>
<year>2014</year>; <volume>9</volume>: <fpage>e92306</fpage>. DOI:
10.1371/journal.pone.0092306.t001.<pub-id pub-id-type="pmid">24647358</pub-id></mixed-citation></ref><ref id="bibr164-0300060519845488"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Highly sensitive visual
detection of Avian Influenza A (H7N9) virus based on the enzyme-induced
metallization.</article-title>
<source>Biosens Bioelectron</source>
<year>2016</year>; <volume>79</volume>: <fpage>874</fpage>&#x02013;<lpage>880</lpage>.
2016/01/23. DOI: 10.1016/j.bios.2016.01.004.<pub-id pub-id-type="pmid">26797249</pub-id></mixed-citation></ref><ref id="bibr165-0300060519845488"><label>165</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Rapid and sensitive
detection of H7N9 avian influenza virus by use of reverse
transcription-loop-mediated isothermal amplification.</article-title>
<source>J Clin Microbiol</source>
<year>2013</year>; <volume>51</volume>: <fpage>3760</fpage>&#x02013;<lpage>3764</lpage>.
2013/09/06. DOI: 10.1128/JCM.01907-13.<pub-id pub-id-type="pmid">24006004</pub-id></mixed-citation></ref><ref id="bibr166-0300060519845488"><label>166</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>JH</given-names></name><name><surname>Im</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>TJ</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Label-free and real-time
detection of avian influenza using nanowire field effect
transistors.</article-title>
<source>J Biomed Nanotechnol</source>
<year>2015</year>; <volume>11</volume>: <fpage>1640</fpage>&#x02013;<lpage>1643</lpage>.
2015/10/22.<pub-id pub-id-type="pmid">26485932</pub-id></mixed-citation></ref></ref-list></back></article>